Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Winter 12-15-2019

Transcriptional Regulation of Adipose Tissue Development by
PexRAP and Med19
John Dean
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Molecular Biology Commons

Recommended Citation
Dean, John, "Transcriptional Regulation of Adipose Tissue Development by PexRAP and Med19" (2019).
Arts & Sciences Electronic Theses and Dissertations. 1997.
https://openscholarship.wustl.edu/art_sci_etds/1997

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Dissertation Examination Committee:
Irfan J. Lodhi, Chair
Brian N. Finck
Charles A. Harris
Babak Razani
Clay F. Semenkovich

Transcriptional Regulation of Adipose Tissue Development by PexRAP and Med19
by
John M. Dean

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

December 2019
St. Louis, Missouri

© 2019, John M. Dean

Table of Contents
List of Figures ................................................................................................................................. v
List of Tables ................................................................................................................................ vii
Acknowledgments........................................................................................................................ viii
Abstract of the Dissertation ........................................................................................................... ix
Chapter 1: Introduction ................................................................................................................... 1
1.1 An Overview of Adipose Tissue ........................................................................................... 1
1.2 Structural and Functional Roles of Ether Lipids ................................................................... 4
1.2.1 Abstract ........................................................................................................................................ 4
1.2.2 Introduction .................................................................................................................................. 5
1.2.3 Biosynthesis of Ether Lipids ........................................................................................................ 6
1.2.4 Biological Functions of Ether Lipids ........................................................................................... 9
1.2.5 Ether Lipids in Disease .............................................................................................................. 15
1.2.6 Concluding Remarks and Future Directions .............................................................................. 19

Chapter 2: PexRAP Inhibits PRDM16-Mediated Thermogenic Gene Expression ...................... 21
2.1 Summary ............................................................................................................................. 22
2.2 Introduction ......................................................................................................................... 22
2.3 Results ................................................................................................................................. 24
2.3.1 Pexrap Expression Profile ................................................................................................ 24
2.3.2 Generation of PexRAP knockout mice ...................................................................................... 25
2.3.3 PexRAP knockout mice have increased browning of subcutaneous white adipose tissue ........ 26
2.3.4 Cell autonomous effect of PexRAP inactivation on thermogenic gene expression ................... 28
2.3.5 Identification of PexRAP-interacting proteins in adipocytes using SILAC .............................. 28
2.3.6 Nuclear localization of PexRAP ................................................................................................ 31
2.3.7 PexRAP interacts with PRDM16 and PPARg and inhibits their interaction with each other ... 32
2.3.8 PexRAP regulates PRDM16-mediated transcriptional activity ................................................. 34

2.4 Discussion ........................................................................................................................... 35
2.5 Experimental Procedures..................................................................................................... 38
2.5.1 RT-PCR ...................................................................................................................................... 38
2.5.2 Pulldown Assays ........................................................................................................................ 38

ii

2.5.3 Measurement of Oxygen Consumption Rate in Adipocytes ...................................................... 39
2.5.4 UCP1-GFP Reporter Assay ........................................................................................................ 39
2.5.5 Cell Culture and Adipocyte Differentiation ............................................................................... 39
2.5.6 Animals ...................................................................................................................................... 40
2.5.7 Plasmids ..................................................................................................................................... 41
2.5.8 Antibodies .................................................................................................................................. 41
2.5.9 SILAC ........................................................................................................................................ 42
2.5.10 Lipid Analysis by Mass Spectrometry ..................................................................................... 42
2.5.11 Subcellular fractionation .......................................................................................................... 43
2.5.12 Chromatin Immunoprecipitation (ChIP) .................................................................................. 43
2.5.13 Statistics ................................................................................................................................... 43

2.6 Supplemental Information ................................................................................................... 44
2.6.1 Supplemental Figures ................................................................................................................. 44
2.6.2 Supplemental Tables .................................................................................................................. 47

Chapter 3: The Mediator Protein Med19 is Essential for White Adipose Tissue Development and
Maintenance .................................................................................................................................. 50
3.1 Abstract ............................................................................................................................... 51
3.2 Introduction ......................................................................................................................... 52
3.3 Results ................................................................................................................................. 54
3.3.1 Generation of Adipose-specific Med19 Knockout Mice ........................................................... 54
3.3.2 Lipoatrophy of White Adipose Tissue in Med19-AKO Mice.................................................... 56
3.3.3 Med19-AKO Mice Have Fatty Liver, Insulin Resistance, and Whitening of Brown Fat. ......... 57
3.3.4 Deletion of Med19 in Mature Adipose Causes Lipoatrophy Due to Increased Apoptosis and
Macrophage Infiltration....................................................................................................................... 58
3.3.5 Med19 Maintains Adipocyte Gene Expression By Facilitating PPARg-Mediated Gene
Expression ........................................................................................................................................... 60

3.4 Discussion ........................................................................................................................... 62
3.5 Materials and Methods ........................................................................................................ 67
3.5.1 Cell Lines ................................................................................................................................... 67
3.5.2 Plasmid Constructs ..................................................................................................................... 68
3.5.3 Mouse Lines ............................................................................................................................... 68
3.5.4 Immunohistochemistry and Immunofluorescence Imaging ....................................................... 69
3.5.5 PPRE Luciferase Assay .............................................................................................................. 69
3.5.6 RT-qPCR .................................................................................................................................... 70

iii

3.5.7 Antibodies .................................................................................................................................. 70
3.5.8 Insulin ELISA and Insulin Signaling Assay .............................................................................. 70
3.5.9 Indirect Calorimetry ................................................................................................................... 71
3.5.10 Ex Vivo Lipolysis Assay .......................................................................................................... 71
3.5.11 RNA-sequencing and Analysis ................................................................................................ 71
3.5.12 Chromatin Immunoprecipitation .............................................................................................. 72
3.5.13 Proximity Ligation Assay......................................................................................................... 72
3.5.14 Pulldown Assays ...................................................................................................................... 73
3.5.15 Statistical Analysis ................................................................................................................... 73

3.6 Supplemental Figures .......................................................................................................... 74
Chapter 4: Future Directions ......................................................................................................... 77
4.1 Delineating the Nuclear Localization and Lipid Synthetic Function of PexRAP in
Adipocyte Differentiation ......................................................................................................... 77
4.2 Determining the Role of Med19 in Brown Adipose Tissue Development and Maintenance
................................................................................................................................................... 79
References ..................................................................................................................................... 85

iv

List of Figures
Figure 1.1 Chemical structures of diacyl and ether-linked phospholipids….………………...…...5
Figure 1.2 Acyl-DHAP pathway of ether lipid synthesis ………………………………….……..8
Figure 1.3 Peroxisomal lipid synthesis is required for maintaining neutrophil viability and
membrane integrity………………………………………………………………………………11
Figure 1.4 Role of ether lipids in Schwann cell differentiation and myelination………………..14
Figure 2.1. PexRAP conditional knockout mice have increased metabolism and browning of
subcutaneous adipose tissue……………………………………………………….………...…...25
Figure 2.2. Identification of PexRAP interacting proteins by SILAC in adipocytes.....................30
Figure 2.3. Nuclear localization of PexRAP..................................................................................32
Figure 2.4. PexRAP interacts with PRDM16 and PPARg and disrupts PRDM16-mediated gene
expression......................................................................................................................................34
Figure S2.1 Generation and characterization of PexRAP knockout-first mice, related to Figure
2.1...................................................................................................................................................44
Figure S2.2 Characterization of PexRAP-iKO mice and the effect of PexRAP knockdown on
UCP1 gene expression in HIB1b cells, related to Figure 1...........................................................45
Figure S2.3 Western blot analysis of PRDM16 and PexRAP and the effect of PexRAP
overexpression on gene expression in BAT SV cells, related to Figure 4.....................................46
Figure 3.1 Lipoatrophy of white adipose tissue in Med19 adipose-specific knockout (Med19AKO) mice.....................................................................................................................................55
Figure 3.2 Med19-AKO mice have fatty liver, increased insulin resistance, and whitening of
brown fat........................................................................................................................................58
Figure 3.3 Deletion of Med19 in mature adipose causes lipoatrophy due to increased apoptosis
and inflammation...........................................................................................................................59
Figure 3.4 Loss of Med19 in mature adipose leads to decreased adipocyte and increased
apoptotic gene expression..............................................................................................................62
Supplemental Figure 3.1 Med19 interacts with PexRAP..............................................................74
v

Supplementary Figure 3.2 Med19 is specifically necessary for white adipogenesis in vitro........75
Supplementary Figure 3.3 Med19-iAKO Mice.............................................................................76
Figure 4.1.1 Schematic of PexRAP mutant constructs..................................................................79
Figure 4.2.1 Med19 knockdown in BAT SV cells has no effect on adipogenesis and enhances
thermogenic gene expression.........................................................................................................81
Figure 4.2.2 Creation of brown adipose-specific Med19 knockout (Med19-BKO) mice.............82

vi

List of Tables
Table S2.1: PexRAP Interacting Proteins Identified Using SILAC, Related to Figure 2.2..........47

vii

Acknowledgments
Science at its best is a community effort. Within our community we rely on our lab mates
for support and our mentors for guidance. I am thankful and indebted to those who came before
me, whose work was a foundation for my own, and also to those around me who I have relied
and learned from throughout my career. I would like to thank my PI, Irfan Lodhi, for guiding and
helping to shape my project, as well as the rest of the Lodhi lab for all their help along the way. I
would like to thank all of my committee members Brian Finck, Charles Harris, Babak Razani,
and Clay Semenkovich for their valuable insight and providing constructive feedback during my
updates. I am thankful for the funding that made this work possible: NIH grants DK115867,
DK118333, DK020579, and T32GM007067.
Lastly, and most importantly, I am forever thankful for all my friends and family that kept me
afloat throughout my time as a graduate student, without you none of this would be possible. And
finally, a very special thanks to my parents for all the help they have given me throughout my
lifetime.

John M. Dean
Washington University in St. Louis
December 2019

viii

Abstract of the Dissertation
Transcriptional Regulation of Adipose Tissue Development by PexRAP and Med19
by
John M. Dean
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2019
Clay F. Semenkovich, Chair
Targeting adipose tissue function to decrease adiposity and improve insulin sensitivity
could treat obesity and diabetes. How the nuclear receptor PPARγ regulates the development of
two functionally distinct types of adipose tissue, brown and white fat (BAT and WAT), as well
as the browning of white fat, remains unclear. Our previous studies suggest that PexRAP, a
peroxisomal lipid synthetic enzyme, regulates PPARγ signaling and white adipogenesis.
Here, we show that PexRAP is an inhibitor of brown adipocyte gene expression. PexRAP
inactivation promoted adipocyte browning, increased energy expenditure, and decreased
adiposity. Identification of PexRAP-interacting proteins suggests that PexRAP function extends
beyond its role as a lipid synthetic enzyme. Notably, PexRAP interacts with importin-β1, a
nuclear import factor, and knockdown of PexRAP in adipocytes reduced the levels of nuclear
phospholipids. PexRAP also interacts with PPARγ, as well as PRDM16, a critical transcriptional
regulator of thermogenesis, and disrupts the PRDM16-PPARγ complex, providing a potential
mechanism for PexRAP-mediated inhibition of adipocyte browning. These results identify
PexRAP as an important regulator of adipose tissue remodeling.
ix

Consistent with the idea that PexRAP is a transcription co-regulator, we also identified
the mediator complex component Med19 as a PexRAP-interacting protein. Mediator is a multisubunit complex that acts as a bridge between transcription factors and RNA PolII. The subunit
composition of Mediator can vary, and different subunits interact with different transcription
factors in a cell context-dependent manner. Many of the specific roles of Mediator subunits,
including Med19, remain unknown.
Here, we demonstrate that Med19 plays a critical role in the development and
maintenance of white fat both in vitro and in vivo, but it is dispensable for brown fat
development. Lentivirus-mediated knockdown of Med19 in iWAT SV cells inhibited
adipogenesis. However, Med19 knockdown in brown adipocytes had no effect on adipogenesis
and appeared to increase thermogenic gene expression. Adipose-specific deletion of Med19
(Med19-AKO) in mice resulted in near ablation of WAT leading to hepatic insulin resistance and
steatosis. BAT mass was unaffected, but Med19-AKO mice manifested a significant whitening
of the thermogenic fat, most likely due to a secondary lipid “spillover” effect caused by white
adipose lipodystrophy. To study the effect of Med19 KO in mature adipose tissue, we created an
adipose-specific, tamoxifen-inducible Med19 knockout (Med19-iAKO) mouse line, which
possessed a similar phenotype to Med19-AKO animals. RNA-seq analysis of Med19-iAKO
gWAT painted a picture of an unhealthy tissue struggling to maintain adipose-specific gene
expression, resulting in loss of adipose tissue, likely due to the upregulation of genes involved in
apoptosis, necroptosis, and inflammation. Chromatin immunoprecipitation (ChIP) in iWAT SV
cells indicated that the decrease in adipose-specific gene expression in Med19-iAKO gWAT is
likely due to reduced residency of PPARγ on adipose-specific target genes. These results identify
Med19 as a crucial facilitator of PPARγ-mediated gene expression that is selectively required for
the development and maintenance of WAT.

x

Chapter 1: Introduction
1.1 An Overview of Adipose Tissue
The epidemic of obesity and diabetes in the United States presents a serious challenge to
the medical and scientific community. Greater than one-third of the adult population is
considered obese (Ogden et al., 2014) and nearly a tenth of adults are diabetic (Association,
2013) with both of these numbers continually growing. These two diseases are closely linked.
Obesity often leads to insulin resistance, making it one of the greatest risk factors for developing
diabetes, a disease with a variety of serious complications that is also associated with premature
death from vascular disease, cancer, and infection (Rao Kondapally Seshasai et al., 2011).
Originally, adipose tissue was believed to be a simple storage depot for excess calories. As our
knowledge has increased, we now know that adipose is a complex endocrine organ that regulates
whole body glucose and lipid metabolism (Galic et al., 2010), making adipose tissue function an
attractive therapeutic target.
Two major types of fat are found in mammals: white and brown fat. Both of these tissues
store energy in the form of intracellular lipid droplets and function to regulate whole body
metabolism through the secretion of a variety of hormones. White adipocytes synthesize
triglycerides that are stored in large, unilocular lipid droplets for long-term energy storage and
release free fatty acids from triglycerides when energy is scarce. Beyond its role as an energy
reserve, white adipose tissue (WAT) is an active endocrine organ producing important adipocyte
secretory products dubbed “adipokines,” such as adiponectin, leptin, and resistin (Ouchi et al.,
2011; Rosen and Spiegelman, 2014).
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In contrast to WAT, brown adipose tissue (BAT) contain multilocular lipid droplets and is
a specialized tissue which dissipates its stored energy in the form of heat during a process called
non-shivering thermogenesis (NST). BAT is present in all placental mammals as an evolutionary
advantage to help maintain body temperature in cold environmental temperatures. For example,
human infants lack developed skeletal muscle and therefore rely on NST from BAT to defend
their body temperature from the extreme temperature change encountered in the post-birth
environment (Shao et al., 2019). This process is facilitated by a protein called uncoupling
protein-1 (UCP1) located in the densely packed mitochondria in BAT. UCP1 creates a proton
leak in the inner mitochondria membrane, effectively uncoupling oxidation from ATP synthesis
and creating a futile cycle which in turn leads to decreased mitochondrial membrane potential,
high substrate oxidation, and the generation of heat. BAT is a highly innervated tissue and the
sympathetic nervous system plays a major part in regulating both the formation and activation of
brown adipose tissue. Upon cold exposure, sympathetic nerves release norepinephrine to activate
thermogenesis and stimulate BAT gene expression (Kajimura et al., 2015). In addition to SNS
stimulation of brown fat, a variety of circulating hormones and lipids have been shown to
regulate BAT thermogenesis (Park et al., 2019a; Rosen and Spiegelman, 2014).
In addition to classical brown fat, UCP1-expressing “beige” cells appear in subcutaneous
WAT in response to various physiological and pharmacological stimuli in a process called
“browning” (Vitali et al., 2012). Although beige cells share many physiological characteristics of
brown fat, they are believed to be derived from a distinct lineage (Sanchez-Gurmaches and
Guertin, 2014; Sanchez-Gurmaches et al., 2016) and arise in WAT at least in part from a smooth
muscle-like precursor (Long et al., 2014) or by conversion of existing white adipocytes (Shao et
al., 2019). Studies on the induction of beige fat formation and activity in mice have shown that
activation of thermogenesis in this tissue can be a powerful strategy towards promoting
2

metabolic health and protecting against weight gain (Dempersmier et al., 2015; Huang et al.,
2017; Svensson et al., 2016).
Until recently, meaningfully amounts of brown fat were thought to be nonexistent in adult
18

humans. This changed when studies using [ F]-FDG PET confirmed the presence of UCP1+
brown adipose tissue that was activated upon cold exposure and also inversely associated with
BMI. (Cypess et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009; Zingaretti
et al., 2009). With these findings, the idea of activating brown/beige adipose activity became an
attractive avenue for treating metabolic disorders in humans (Harms and Seale, 2013).
UCP1 expression in both brown and beige fat is reliant upon the activity of PRDM16
(Cohen et al., 2014; Seale et al., 2007). PRDM16 acts to control thermogenic gene expression by
interacting with and modulating the activity of other transcription factors including C/EBPβ,
PPARγ, PPARα and PGC-1α (Harms and Seale, 2013; Kajimura et al., 2009; Seale et al., 2008)
rather than by direct, sequence-specific DNA binding. Ectopic expression of PRDM16 is capable
of converting myoblasts and white fat precursors into UCP1 expressing thermogenic cells,
suggesting that it is a driving factor in both beige and brown adipogenesis (Seale et al., 2008).
Conversely, knockdown of PRDM16 leads to an increase in expression of white fat and musclespecific genes (Seale et al., 2007, 2008).
PPARg, is widely considered as the master regulator of adipogenesis and plays a crucial
role in whole body metabolism and insulin sensitivity (Ahmadian et al., 2013; Tontonoz and
Spiegelman, 2008). It is part of a family of nuclear receptors that are fundamentally important in
energy metabolism and homeostasis called the PPARs or peroxisome proliferator activated
receptors (Wang, 2010). PPARs are ligand inducible transcription factors that form obligate
heterodimers with the retinoid X receptors to drive target gene expression. Both white and brown
adipocytes require PPARg for their development and maintenance (Wang et al., 2013),
3

suggesting that various PPARg cofactors and other transcription regulators are important for
conferring WAT and BAT their unique properties. Many adipogenic transcription factors work
to induce PPARg expression in order to drive adipocyte differentiation such as C/EBPa,
C/EBPb, C/EBPd, STAT5, EBF1, and many KLF family members (de Sá et al., 2017). PPARg
was originally identified as the target of the glitazone class of drugs used to treat diabetes
(Ahmadian et al., 2013). While some fatty acids and their derivatives, such as ether lipids
(Davies et al., 2001; McIntyre et al., 2003; Tsukahara et al., 2006; Zhang et al., 2004), have been
shown to bind and activate PPARg, they bind with a much lower affinity than glitazones,
suggesting an incomplete understanding of endogenous PPARg activation. (Tzameli et al., 2004).

1.2 Structural and Functional Roles of Ether Lipids
The following work was written by me and Irfan J. Lodhi and appeared in its entirety in
Protein & Cell (Dean, J.M. & Lodhi, I.J. Structural and Functional Roles of Ether Lipids. Protein
& Cell (2018) 9: 196. https://doi.org/10.1007/s13238-017-0423-5). The work was supported by
NIH grant R00 DK094874 and T32GM007067.

1.2.1 Abstract
Ether lipids, such as plasmalogens, are peroxisome-derived glycerophospholipids in
which the hydrocarbon chain at the sn-1 position of the glycerol backbone is attached by an ether
bond, as opposed to an ester bond in the more common diacyl phospholipids. This seemingly
simple biochemical change has profound structural and functional implications. Notably, the
tendency of ether lipids to form non-lamellar inverted hexagonal structures in model membranes
suggests that they have a role in facilitating membrane fusion processes. Ether lipids are also
important for the organization and stability of lipid raft microdomains, cholesterol-rich
membrane regions involved in cellular signaling. In addition to their structural roles, a subset of
4

ether lipids is thought to function as endogenous antioxidants, and emerging studies suggest that
they are involved in cell differentiation and signaling pathways. Here, we review the biology of
ether lipids and their potential significance in human disorders, including neurological diseases,
cancer and metabolic disorders.

1.2.2 Introduction
Conventional glycerophospholipids have acyl chains attached to the sn-1 and sn-2
positions of the glycerol backbone by ester bonds. Ether lipids are a unique class of
glycerophospholipids that have an alkyl chain attached to the sn-1 (Figure 1.1) position by an
ether bond. The alcohol moiety attached to the phosphate group in ether lipids is generally
choline or ethanolamine, but occasionally inositol or serine have also been observed. Ether lipids
constitute approximately 20% of the total phospholipid pool in mammals, but tissue distribution
varies. The highest levels are found in the brain, heart, spleen, and white blood cells, while liver
has scant amount of intracellular ether lipids (Braverman and Moser, 2012).

Figure 1.1 Chemical structures of diacyl and ether-linked phospholipids. Diacyl phospholipids have fatty acyl
side chains linked to the sn-1 and sn-2 position of the glycerol backbone by ester bonds. Ether-linked phospholipids
are a subclass of glycerophospholipids that have an alkyl chain attached by an ether bond at the sn-1 position. The
sn-2 position of ether lipids generally has an ester-linked acyl chain, as in diacyl phospholipids. Some ether-linked
phospholipids, called alkenyl-acylphospho- lipids, contain a cis double bond adjacent to the ether linkage and are
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commonly referred to as plasmalogens. The polar head group of ether-linked phospholipids is most commonly
choline or ethanolamine.

Plasmalogens are the most common form of ether lipids and are characterized by a cis
double bond adjacent to the ether linkage. Plasmalogens were serendipitously discovered in 1924
by Feulgen and Voit while staining tissue sections with a nuclear stain that reacts with aldehydes
released by acid hydrolysis of DNA (Snyder, 1999). Because the acid treatment also resulted in
breakdown of the vinyl ether bond of plasmalogens to generate aldehydes, the researchers
unexpectedly also observed cytoplasmic staining and named the unknown source of aldehydes
“plasmalogens”. The study of plasmalogens and ether lipids in general has been long and
arduous and in the beginning the progress was slow and scattered. Recently, much advancement
has been made in our understanding of the roles of ether lipids in health and disease.
In this review, we outline the pathway of ether lipid biosynthesis and then describe the
unique structural roles played by ether lipids in mammalian cell membranes, followed by a
discussion of emerging cellular functions of these lipids. Lastly, we review the current
knowledge of the role of ether lipid metabolism in disease.

1.2.3 Biosynthesis of Ether Lipids
Ether lipids are synthesized through a well-characterized process that begins in the
peroxisome and is completed in the ER (Figure 1.2). The peroxisomal component is referred to
as the acyl-dihydroxyacetone (DHAP) pathway since DHAP, a glycolysis intermediate, is used
as a precursor for ether lipid synthesis (Hajra and Das, 1996). Fatty acids for ether lipid synthesis
are thought to be derived from fatty acid synthase (FAS)-mediated de novo lipogenesis or dietary
sources (Lodhi et al., 2012, 2015). FAS, a large multifunctional enzyme that primarily
synthesizes palmitate (C16:0), is partially localized to the peroxisomes, where it interacts with
6

various peroxisomal proteins (Cader et al., 2016; Hillebrand et al., 2012; Lodhi et al., 2012). In
order to be used for ether lipid synthesis, fatty acids are first activated to fatty acyl-CoAs by an
acyl-CoA synthetase (ACS) associated with the peroxisomal membrane. Glyceronephosphate Oacyltransferase (GNPAT), a peroxisomal matrix protein, uses a long chain acyl-CoA to acylate
DHAP at the sn-1 position. The next peroxisomal step is catalyzed by alkylglycerone phosphate
synthase (AGPS) and results in the formation of the ether bond at the sn-1 position by
exchanging an acyl chain for an alkyl group. The alkyl moiety used in the AGPS-catalyzed step
is generated by a peroxisomal membrane-associated fatty acyl-CoA reductase (FAR1 or FAR2),
which reduces an acyl-CoA to a fatty alcohol. The final peroxisomal step in ether lipid synthesis
is carried out by acyl/alkyl-DHAP reductase, which reduces alkyl-DHAP into the ether lipid
precursor 1-O-alkyl glycerol-3-phosphate (AGP). The DHAP reductase can also reduce acylDHAP to generate the diacyl phospholipid precursor lysophosphatidic acid (LPA) as an
alternative to direct acylation of glycerol-3-phosphate (G3P) by a G3P acyltransferase (GPAT).
Further steps to convert AGP or LPA to corresponding ether-linked or diacyl glycerolipids, such
as phosphatidylcholine or phosphatidylethanolamine, take place in the ER. Tethering of
peroxisomes to the ER for completion of lipid synthesis was recently shown to involve
interaction of the peroxisomal protein acyl-CoA-binding domain 5 (ACBD5) with VAMPassociated proteins A and B (VAPA and VAPB), ER-resident proteins that recruit organelles to
the ER (Hua et al., 2017). The precise mechanism through which the ACBD5-VAP complex
permits exchange of lipids between the organelles is unclear.

7

Figure 1.2 Acyl-DHAP pathway of ether lipid synthesis. This process begins in peroxisomes and is subsequently
completed in the ER. The pathway utilizes dihydroxyacetone phosphate (DHAP) generated by glycerol 3-phosphate
dehydrogenase (G3PDH)-mediated dehydrogenation of G3P as the substrate for ether lipid synthesis. Fatty acid
synthase (FAS)-mediated de novo lipogenesis generates fatty acyl-CoA that is utilized by glyceronephosphate Oacyltransferase (GNPAT) or reduced to a fatty alcohol by a fatty acyl-CoA reductase (FAR1 or FAR2) to later be
catalyzed by alkylglycerone phosphate synthase (AGPS), forming the ether bond and exchanging the acyl chain for
an alkyl group. PexRAP (an acyl/alkyl DHAP reductase) then catalyzes the final peroxisomal step, generating the
ether lipid precursors, 1-O-alkyl-G3P (AGP) or the diacyl phospholipid precursor lysophosphatidic acid (LPA). The
completion of phospholipid synthesis occurs in the ER. This includes acylation of the glycerol backbone at the sn-2
position, converting LPA to diacylglycerol (DAG) and AGP to alkyl-acylglycerol (AAG), as well as addition of a
cytidine diphosphate-alcohol head group (such as CDP-choline or CDP-ethanolamine) at the sn-3 position to form
the mature phospholipid.

Although the acyl/alkyl-DHAP reductase protein was purified from guinea pig liver and
characterized over 40 years ago (LaBelle and Hajra, 1974), the gene encoding this enzyme in
mammals remained unknown. We recently identified this gene as dhrs7b and renamed the
protein PexRAP (for Peroxisomal Reductase Activating PPARg) based on its proposed function
in adipose tissue (Lodhi et al., 2012). Unlike inactivation of GNPAT (also called DHAP
acyltransferase), which results in almost complete loss of ether lipids (Rodemer et al., 2003),
knockout of PexRAP in mice results in 50-80% decrease in the ether lipid levels (Lodhi et al.,
2015). Similarly, approximately 50% decrease in ether lipids was observed in a mutant of CHOK1 cells with almost complete absence of acyl/alkyl DHAP reductase activity isolated in an ethyl
methanesulfonate (EMS) mutagenesis screen (James et al., 1997), suggesting that there is a
8

salvage pathway of ether lipid synthesis. The precise nature of this salvage pathway is poorly
understood, but is thought to involve dephosphorylation of alkyl-DHAP to alkyldihydroxyacetone, followed by its reduction to alkyl-glycerol, which upon phosphorylation can
re-enter the biosynthetic pathway downstream of acyl/alkyl-DHAP reductase (James et al.,
1997).

1.2.4 Biological Functions of Ether Lipids
Ether lipids are chemically distinct from their diacyl counterparts, allowing them to
contribute unique structural characteristics to biological membranes, which affect such factors as
membrane fluidity and membrane fusion. In addition to these effects on membrane dynamics,
studies with in vitro and in vivo models of ether lipid deficiency suggest that ether lipids are
involved in a variety of biological functions, including regulating cell differentiation, impacting
cellular signaling, and reducing oxidative stress through their ability to function as potential
endogenous antioxidants.
Structural Roles
Ether lipids are a major structural component of cell membranes. The incorporation of
ether-linked alkyl chains in phospholipids alters their physical properties and affects membrane
dynamics. This is largely attributed to the lack of a carbonyl oxygen at the sn-1 position, which
facilitates stronger intermolecular hydrogen bonding between the headgroups (Lohner, 1996).
Moreover, the vinyl-ether linkage of plasmalogens at the sn-1 position allows the proximal
regions of the sn-1 and sn-2 chains to become parallel, favoring close alignment (Han and Gross,
1990; Paltauf, 1994), therefore permitting tighter packing of phospholipids in the membrane
resulting in decreased membrane fluidity and increased rigidity. This property is particularly
important in higher order membrane structures such as those found in myelin, evidenced by its
enrichment in plasmalogens (Farooqui and Horrocks, 2001). Both ether lipid-deficient mouse
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models and human patients with ether lipid deficiency often display defects in myelination in
both the central and peripheral nervous systems (da Silva et al., 2012).
Plasmalogens are enriched in lipid raft microdomains (LRM), cholesterol-rich regions of
membranes where many cellular signaling proteins are concentrated (Pike et al., 2002; Rodemer
et al., 2003). Recently, lipidomic analysis of rat synaptic membranes during the first 60 days of
postnatal development showed dynamic changes in membrane lipids, including the progressive
accumulation of plasmalogens along with cholesterol and sphingolipids. Reconstitution of this
membrane remodeling in a model membrane system was associated with enhancement of raft
domain stability (Tulodziecka et al., 2016). Consistent with the requirement of plasmalogens in
the organization of LRM, plasmalogen-deficient GNPAT knockout mice display disrupted lipid
raft formation and mislocalization of cholesterol to a perinuclear compartment (Rodemer et al.,
2003).
Disruption of cellular phospholipid composition affects membrane integrity (Li et al.,
2006), activates ER stress (Fu et al., 2011; Volmer et al., 2013), and promotes apoptosis (Yen et
al., 1999). It has long been known that ether-linked phospholipids are abundantly present in
neutrophils, constituting nearly half of the phosphatidylcholine pool (Bräutigam et al., 1996;
Mueller et al., 1982, 1984; Nagan and Zoeller, 2001). However, the physiological significance of
these lipids in neutrophils has remained unclear. Our recent studies with genetic inactivation of
lipogenesis in mice suggest that ether lipids are an important membrane component required for
survival of mature neutrophils (Figure 1.3). Tamoxifen-inducible global knockout of FAS
results in a preferential decrease in ether-linked glycerophosphocholines (ether-lipid equivalent
of phosphatidylcholine; GPC) in neutrophils (Lodhi et al., 2015), increased ER stress and
apoptosis, resulting in nearly complete neutropenia, suggesting that FAS channels fatty acids to
peroxisomes for lipid synthesis. Indeed, FAS has been shown to interact with PMP70, an ATP
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binding cassette subfamily D transporter that transports fatty acyl CoA into peroxisomes
(Hillebrand et al., 2012), directly linking FAS to peroxisomal lipid metabolism. Consistent with
the importance of peroxisome-derived lipids in neutrophil survival, tamoxifen-inducible
knockout of PexRAP also results in neutropenia due to decreased ether lipid levels,
recapitulating the results obtained with FAS knockout (Lodhi et al., 2015). These results suggest
that peroxisome-derived lipids, including ether lipids, are an important structural component of
neutrophil membranes and reveal a novel lipogenic pathway that selectively regulates neutrophil
development.

Figure 1.3 Peroxisomal lipid synthesis is required for maintaining neutrophil viability and membrane
integrity. In healthy neutrophils, fatty acid synthase (FAS) and PexRAP participate in peroxisomal lipid synthesis,
including the generation of ether-linked phospholipids that are incorporated into the plasma membrane, contributing
to membrane integrity. Genetic ablation of FAS or PexRAP disrupts the lipid synthetic pathway, leading to a
preferential loss of ether-linked phospholipids in neutrophils. This alters membrane stability, leading to the
activation of ER stress, increased apoptosis, and ultimately neutropenia.

Membrane Trafficking
Model membranes enriched in plasmalogens have a greater tendency to form nonlamellar inverse hexagonal structures at lower temperatures as compared to such membranes
composed of diacyl phospholipids (Glaser and Gross, 1994). Since a transition from a lamellar
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(no curvature) to an inverted hexagonal (negative curvature) phase is required for membrane
fusion (Marrink and Mark, 2004), this property of plasmalogens has been linked to their role in
facilitating processes of membrane trafficking. Notably, synaptic vesicles are enriched in ether
lipids, and neurotransmitter release from these vesicles into the presynaptic cleft is impaired in
the synaptosomes (nerve terminals) isolated from the brains of ether lipid deficient mice (Brodde
et al., 2012). In further support of the notion that ether lipids facilitate membrane fusion
processes, ether lipid deficiency disrupts the integrity of the blood-testis barrier by affecting the
sorting, endocytosis, and recycling of tight junction proteins (Komljenovic et al., 2009).
Moreover, plasmalogens have been implicated in cholesterol transport. CHO cells with a defect
in plasmalogen synthesis have impaired plasma membrane to ER transport and esterification of
cholesterol (Munn, 2003). It is unclear whether plasmalogens directly regulate cholesterol
transport through effects on membrane dynamics or if a signaling molecule released from
hydrolysis of plasmalogens is involved in the process.
Cell Signaling and Differentiation
In addition to their structural roles, ether lipids can also act as biological signaling
molecules. Oxidation of the vinyl-ether bond of plasmalogens by brominating species produced
by an eosinophil peroxidase in activated eosinophils results in a a-bromo fatty aldehyde that acts
as a phagocyte chemoattractant for the recruitment of other leukocytes to sites of inflammation
(Albert et al., 2003; Thukkani et al., 2002). Moreover, ether-linked mono-alkyl
glycerophosphates serve as endogenous antigens to activate invariant natural killer T (iNKT)
cells. GNPAT-deficient mice show impaired thymic maturation of iNKT cells and have a
reduced overall number of iNKT cells in the thymus and periphery, suggesting that ether lipids
are important for the development of these cells (Facciotti et al., 2012).
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Ether lipids have also been identified as potential endogenous ligands of peroxisome
proliferator-activated receptor gamma (PPARg) (Davies et al., 2001; McIntyre et al., 2003;
Tsukahara et al., 2006; Zhang et al., 2004), a nuclear receptor critical for adipose tissue
development and lipid metabolism, which is the target of the glitazone family of diabetes drugs.
Using an unbiased mass spectrometry-based approach, we identified several ether-linked GPC
species that were bound to PPARg in a rosiglitazone-displaceable manner. Treatment of cells
with one of these lipid species promoted PPARg-dependent luciferase reporter activity (Lodhi et
al., 2012). Furthermore, inhibition of ether lipid biosynthesis by knockdown of PexRAP blocks
PPARg dependent gene expression and adipocyte differentiation. This effect was rescued by
rosiglitazone treatment, suggesting that peroxisomal lipid synthesis is involved in endogenous
ligand generation (Lodhi et al., 2012). Recently, disruption of peroxisomal biogenesis by Pex16
knockdown was shown to impair PPARg activation and adipocyte differentiation. The defect in
adipogenesis was rescued with the treatment of alkyl glycerol (Hofer et al., 2017), an ether lipid
precursor that enters the synthetic pathway downstream of the peroxisomal steps.
Ether lipids have also been implicated in the differentiation of other cell types. In the
peripheral nervous system, Schwann cells are required for maintaining axonal health and
myelination. Impaired ether lipid synthesis is associated with defects in myelination and myelin
structure (Brites, 2003; Rodemer et al., 2003; Teigler et al., 2009). Recent studies suggest that
this may be related to the requirement of plasmalogens in Schwann cell differentiation and
function. Plasmalogen deficiency mediated by GNPAT or Pex7 knockout in mice impairs
membrane recruitment and activation of Akt, resulting in hyperactivation of glycogen synthase
kinase 3β (GSK3β), which inhibits Schwann cell differentiation (Figure 1.4). This in turn
impairs axonal sorting and myelination. Inhibition of GSK3β using lithium rescues Schwann cell
differentiation, bypassing the effect of plasmalogen deficiency (da Silva et al., 2014).
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Plasmalogens have also been implicated in Akt signaling in other cell types. Plasmalogens
protect against apoptosis induced through serum starvation by modulating Akt signaling, a
pathway possibly mediated through plasmalogens’ ability to activate G-protein coupled receptor
signaling (Hossain et al., 2013, 2016). Supplementation of Neuro-2 cells with plasmalogens
suppress neuronal apoptosis signaling induced via serum starvation (Yamashita et al., 2015a).

Figure 1.4 Role of ether lipids in Schwann cell differentiation and myelination. In a healthy Schwann cell, the
cell membrane is enriched in plasmalogens. This is necessary for proper recruitment of Akt to the plasma
membrane, resulting in its phosphorylation and activation. Activated Akt phosphorylates GSK3β at Ser9, inhibiting
its activity. Plasmalogen deficiency impairs recruitment and activation of Akt, preventing it ability to inhibit
GSK3β. Active GSK3β impairs Schwann cell differentiation, resulting in disrupted radial sorting and myelination.
Supplementation of lithium or TDZD-8 to inhibit GSK3β rescues plasmalogen-deficient phenotype, restoring
differentiation and myelination.

Plasmalogens as Cellular Antioxidants
Plasmalogen-deficient cultured cells and animals have long been known to be more
sensitive to oxidative damage as compared to their wild-type counterparts, setting the basis for
the notion that plasmalogens may function as cellular antioxidants (Morand et al., 1988; Reiss et
al., 1997; Zoeller et al., 1988). This is thought to be due to the presence of the vinyl ether bond,
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which makes plasmalogens susceptible to oxidative attacks. In particular, there is evidence to
suggest that plasmalogens could protect unsaturated membrane lipids from oxidation by singlet
oxygen (Broniec et al., 2011). Plasmalogens may also be involved in scavenging a variety of
reactive oxygen species (ROS) (Khaselev and Murphy, 1999; Maeba and Ueta, 2003; Maeba et
al., 2002; Morand et al., 1988; Skaff et al., 2008; Yavin and Gatt, 1972). Recent studies suggest
that myelin in sciatic and optic nerves from plasmalogen-deficient mice lacking the peroxisomal
biogenesis factor Pex7 is significantly more susceptible to oxidative damage then the myelin
from wild-type mice (Luoma et al., 2015).
The idea that plasmalogens have a protective role against oxidative damage is difficult to
validate directly in complex biological systems. Moreover, even pro-oxidant effects of these
lipids have been reported in a bulk lipid system (Wang and Wang, 2010). A recent study using
synthetic choline plasmalogens in model membrane systems suggests that the antioxidant effect
of plasmalogens occurs intramolecularly rather than intermolecularly and depends on the degree
of unsaturation of the sn-1 and sn-2 chains, the length of these chains, and their conformation in
membranes (Broniec et al., 2017). This suggests that the antioxidant capacity of plasmalogens
may be contextually dependent.

1.2.5 Ether Lipids in Disease
The critical importance of ether lipids for health in humans is highlighted by the severity
of inherited peroxisomal disorders caused by ether lipid deficiency. Emerging studies suggest
that altered ether lipid production is also associated with several other disorders including
neurodegenerative diseases, cancer and metabolic disorders. However, the molecular
mechanisms underlying the role of ether lipids in these diseases remain unclear for the most part,
suggesting a need for future research.
Peroxisomal disorders
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Rhizomelic Chondrodysplasia Punctata (RCDP) is a peroxisomal disorder caused by
ether lipid deficiency. RCDP is a multisystem, developmental disorder and has a rare occurrence
affecting approximately 1/100,000 individuals. Symptoms include not only those that give the
disease its namesake, shortening of limbs (rhizomelia) and multiple punctate epiphyseal
calcification (chondrodysplasia punctata), but also microcephaly, distinct facial features,
cataracts, and psychomotor retardation. The disease is fatal with patients rarely surviving past the
tenth year of life (White et al., 2003). The most common form is RCDP type 1, which is caused
by mutations in Pex7, a peroxisomal import receptor for proteins, including AGPS, that contain a
type 2 peroxisomal targeting sequence (PTS), resulting in defects in peroxisomal biogenesis
(Braverman et al., 1997; Motley et al., 1997; Purdue, 1997). The less common RCDP types 2 and
3 are caused by single enzyme mutations in either the GNPAT or AGPS genes, respectively, and
result in deficient ether lipid biosynthesis. Recently, two new types of RCDP have been reported.
RCDP type 4 results from a mutation in FAR1, which is required for the conversion of fatty acylCoAs to fatty alcohols (Buchert et al., 2014; Honsho et al., 2013). RCDP type 5 results from a
genetic mutation leading to specific loss of only the Pex5 long isoform (Pex5L). While both the
long and short Pex5 isoforms recognize PTS1-containing proteins, Pex5L is a co-receptor with
Pex7 for the import of PTS2-containing proteins, and its loss results only in impaired PTS2tagged protein import and RCDP phenotype (Barøy et al., 2015).
Generation of mouse models of ether lipid deficiency has shed some light on the
pathophysiology of peroxisomal biogenesis disorders. These mice show defects in neuronal
development and myelination (Brites, 2003; Rodemer et al., 2003; Teigler et al., 2009). As
discussed above, Schwann cells of ether-lipid deficient mice show impaired differentiation and
myelination resulting from decreased Akt signaling, presumably due to the necessity of
plasmalogens for correct recruitment of Akt to the membrane (da Silva et al., 2014).
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Neurological disorders
Alzheimer’s disease (AD) pathology is associated with decreased ether lipids,
particularly plasmalogens, in the brain (Ginsberg et al., 1995, 1998; Han, 2005; Han et al., 2001).
Additionally, serum levels of ethanolamine plasmalogens in AD patients are decreased and
correlate with the severity of disease progression (Goodenowe et al., 2007; Wood et al., 2010).
Given this relationship, serum plasmalogen levels have even been used to successfully stratify
diseased patients (Wood et al., 2016). Increased b-amyloid (Aβ) levels associated with AD have
been shown to promote oxidative stress in the brain, leading to loss of peroxisomal function.
This in turn decreases AGPS (the rate-limiting enzyme of ether lipid synthesis) activity,
ultimately lowering plasmalogen levels (Grimm et al., 2011). In addition, certain ethanolamine
plasmalogen species are thought to have the ability to destabilize existing Aβ fibrils in vitro and
prevent the formation of new fibrils in a dose dependent manner, providing another mechanism
by which plasmalogen loss facilitates AD pathology (Yamashita et al. J Alzheimer's 2015).
Abnormal ether lipid levels have also been implicated in other neurological disorders.
Red blood cells and fibroblasts collected from schizophrenia patients were recently shown to be
significantly decreased in plasmalogen levels (Huang et al., 2016; Tessier et al., 2016). In
addition, patients with Parkinson’s disease show severe alterations in neuronal membrane
composition, including a significant decrease in postmortem frontal cortex lipid raft
plasmalogens levels (Fabelo et al., 2011). Additional work is needed to understand the molecular
mechanism through which reduced ether lipids contribute to these pathologies.
Cancer
Decades ago it was observed that cancer cells have remarkably higher levels of ether
lipids compared to normal cells, suggesting that ether lipids may be involved in cancer
pathogenesis (Snyder et al. 1966, 1969; Snyder and Wood 1969; Albert and Anderson 1977;
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Roos and Choppin 1984). Indeed, increased ether lipids are correlated with more aggressive
cancers, and knockdown of AGPS in a variety of cancer cell lines results in impaired
pathogenicity (Benjamin et al., 2013). A small molecule screen identified an inhibitor of AGPS
that decreases ether lipid levels and appears to reduce pathogenicity of human cancer cells in
vitro (Piano et al., 2015). Recently, a lipidomics study on breast cancer patients identified
increased plasma ether-linked phosphatidylcholine species as a diagnostic marker for breast
cancer (Chen et al., 2016).
Metabolic Disorders
Levels of plasmalogen and other ether-linked phosphatidylcholine species are increased
in steatotic livers of high fat diet-fed mice, although, it is unclear whether this is due to increased
synthesis, reduced degradation, or impaired hepatic release (Eisinger et al., 2014). One
possibility is that increased plasmalogens may be an indication of increased activity of protective
mechanisms against oxidative stress (Barr et al., 2012). However, serum plasmalogen levels are
decreased in patients with nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
disease (NAFLD) as compared to healthy controls (Puri et al., 2009). This drop in plasmalogen
levels is more severe in NASH patients as opposed to simple steatosis patients suggesting the
possibility to use serum lipidomics as a biomarker to diagnose and stratify the disease. Recent
studies suggest a protective role of plasmalogens against NASH. Free cholesterol-induced NASH
in mice was associated with decreased levels of docosahexaenoic acid-containing plasmalogens
and impaired expression of PPARa, a critical transcriptional regulator of fatty acid oxidation.
Rescue of plasmalogen levels by alkyl glycerol treatment prevented hepatic steatosis and NASH
through PPARa-dependent increase in fatty acid oxidation, suggesting a role for endogenous
plasmalogens production in PPARa signaling (Jang et al. 2017).
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Decreased serum ether lipid levels are also associated with hypertension and obesity
(Graessler et al., 2009; Pietiläinen et al., 2007). In a weight-discordant twin study, obese patients
showed a decrease in serum plasmalogens compared to healthy twin controls, indicating that the
effect is independent of genetic makeup (Pietiläinen et al., 2007). Similarly, a follow up study by
the same group showed that plasmalogens containing arachidonic acid are reduced in the
adipocyte membranes of morbidly obese twins compared to metabolically healthy twins
(Pietiläinen et al., 2011). Conversely, serum plasmalogen levels increase in men with aerobic
training and in patients with a healthy dietary intervention (Felder et al., 2017; Lankinen et al.,
2016). Interestingly, decreased ether lipids were detected in the serum of children that were later
diagnosed with type 1 diabetes. The presence of these metabolic changes prior to the detection of
autoantibodies suggests that ether lipid metabolism is dysregulated before the disease emerges
and thus may contribute to accelerating pathology (Orešič et al., 2008).

1.2.6 Concluding Remarks and Future Directions
With the rising interest in lipidomics, ether lipids have emerged as potential biomarkers
of several diseases, including neurodegenerative diseases, cancer and metabolic disorders
(Alshehry et al., 2016; Chen et al., 2016; Eisinger et al., 2014; Tessier et al., 2016). However,
with this observation comes the principal question: Are the changes in ether lipid levels merely a
byproduct of the disease process or a contributor to disease pathogenesis? Severe phenotypes
resulting from genetic loss of ether lipid production suggest that these peroxisome-derived
phospholipids are responsible for fundamental cellular functions that cannot be carried out by
conventional phospholipids. Decreased ether lipid synthesis is linked to multiple neurological
and metabolic abnormalities, while increased levels are associated with cancer, suggesting that
proper regulation of ether lipid production is required for normal physiology. Future research
will be necessary to determine if targeted inhibition of the ether lipid synthetic pathway could
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treat malignancies. Conversely, there is a need to develop novel dietary interventions to correct
pathologies associated with ether lipid deficiency. Several groups have attempted to deliver
alkylglycerols in diet to boost ether lipid levels in deficient animals with variable results. While
the effects of ether lipid replacement appear to be promising in peripheral tissues, the results
have been less successful in correcting neurological deficits (Brites et al., 2011; Jang et al., 2017;
Rasmiena et al., 2015). It will be of great interest to develop more effective synthetic ether lipid
precursors that could cross the blood-brain barrier and alter the clinical course of neurological
diseases.
Currently there is a wide knowledge gap between what is known about the normal
cellular functions of ether lipids and the molecular mechanisms underlying the pathologies
associated with altered production of these lipids. Much work has been done using mouse
models of global ether lipid deficiency, revealing gross abnormalities associated with such
manipulations (da Silva et al., 2012). Going forward it will be important to take a more finetuned approach through targeted inactivation of ether lipid production to better define the
biological roles of these unique phospholipids, perhaps uncovering novel strategies for disease
intervention.
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2.1 Summary
How the nuclear receptor PPARg regulates the development of two functionally distinct
types of adipose tissue, brown and white fat, as well as the browning of white fat, remains
unclear. Our previous studies suggest that PexRAP, a peroxisomal lipid synthetic enzyme,
regulates PPARg signaling and white adipogenesis. Here, we show that PexRAP is an inhibitor
of brown adipocyte gene expression. PexRAP inactivation promoted adipocyte browning,
increased energy expenditure, and decreased adiposity. Identification of PexRAP-interacting
proteins suggests that PexRAP function extends beyond its role as a lipid synthetic enzyme.
Notably, PexRAP interacts with importin-b1, a nuclear import factor, and knockdown of
PexRAP in adipocytes reduced the levels of nuclear phospholipids. PexRAP also interacts with
PPARg, as well as PRDM16, a critical transcriptional regulator of thermogenesis, and disrupts
the PRDM16/PPARg complex, providing a potential mechanism for PexRAP-mediated
inhibition of adipocyte browning. These results identify PexRAP as an important regulator of
adipose tissue remodeling.

2.2 Introduction
The continued global rise in obesity and its associated insulin resistance and diabetes
calls for alternative treatment approaches. Targeting adipose tissue function to decrease adiposity
and improve insulin sensitivity represents such an approach. Adipose tissue is a complex organ
that regulates whole body energy balance (Rosen and Spiegelman, 2014). Two major types of
adipose tissue are found in mammals: white fat and brown fat. White adipose tissue (WAT)
primarily stores fat, which can be mobilized in times of need, whereas brown adipose tissue
(BAT) transforms the chemical energy in food into heat through uncoupled respiration. In
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addition to classical brown adipocytes, clusters of brown adipocyte-like beige cells appear in
subcutaneous WAT in response to prolonged cold exposure or beta adrenergic signaling (Wang
and Seale, 2016). Brown and beige adipocytes are characterized by their expression of
uncoupling protein-1 (UCP1), a long chain fatty acid/H+ symporter (Fedorenko et al., 2012) that
mediates thermogenesis by allowing protons to leak across the inner mitochondrial membrane,
bypassing ATP synthase. By promoting thermogenesis, this uncoupling of oxidation from ATP
production increases energy expenditure. Thus, exploiting the thermogenic capacity of brown
and beige adipocytes represents a potential strategy for treating obesity and diabetes.
Thermogenic gene expression in both types of UCP1-positive adipocytes is regulated by
PRDM16, a large zinc-finger containing transcription factor (Cohen et al., 2014; Harms et al.,
2014; Seale et al., 2007). Overexpression of PRDM16 in adipocyte precursors or in mice
promotes brown gene expression (Seale et al., 2008). Conversely, adipose-specific deletion of
PRDM16 inhibits browning of subcutaneous WAT and promotes obesity and insulin resistance
(Cohen et al., 2014). PRDM16 does not appear to be required for embryonic development of the
classical BAT, but is necessary to repress white-fat-selective genes within BAT and to maintain
brown adipocyte function in adult mice (Harms et al., 2014; Ohno et al., 2013). PRDM16
regulates thermogenic gene expression by interacting with and modulating the activity of other
transcription factors, including C/EBPa, PGC1a, PPARg and PPARa (Kajimura et al., 2009;
Seale et al., 2008).
The ligand-activated nuclear receptor PPARg is a critical transcriptional regulator of both
white and brown adipose tissue development (Ahmadian et al., 2013). Ligand binding induces a
conformational change in PPARg, promoting dissociation of transcriptional repressors and
recruitment of co-activators, resulting in activation of target gene expression. Because PPARg
can regulate development of the two functionally distinct types of adipose tissue, as well as
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browning of white adipose tissue, it is likely that PPARg is activated by multiple endogenous
partial agonists that in turn recruit different transcriptional co-activators controlling unique
subsets of genes.
Our previous efforts to understand the role of adipose tissue lipogenesis in PPARg
signaling led to the identification of PexRAP (Peroxisomal Reductase Activating PPARg), a
peroxisomal membrane protein that synthesizes ether-linked phospholipids, potential partial
agonists for PPARg (Lodhi et al., 2012). Here, we demonstrate that PexRAP is a multifunctional
protein that appears to act as a molecular switch to represses adipocyte browning.

2.3 Results
2.3.1 Pexrap Expression Profile
We previously identified PexRAP as a protein involved in adipogenesis that is enriched
in cellular fractions containing peroxisomal markers such as PMP70 and catalase (Lodhi et al.,
2012). To determine the relative distribution of PexRAP in different adipose tissue depots, we
isolated inguinal, gonadal, and brown adipose tissues from wild-type (WT) C57 mice fed chow
diet (Figure 2.1). Western blot analysis indicated that the PexRAP protein was expressed in
WAT depots, but its levels in BAT were low (Figure 2.1A). PexRAP protein levels were also
decreased in iWAT of mice subjected to cold exposure for one week (Figure S2.1A). These data
suggest that PexRAP might be a negative regulator of thermogenic gene expression and is
maintained at low levels during BAT development or cold-induced browning of WAT.

24

Figure 2.1. PexRAP conditional knockout mice have increased metabolism and browning of subcutaneous
adipose tissue. (A) Western blot analysis of PexRAP expression in different adipose depots of WT C57 mice.
Panels B-E, tamoxifen-inducible global PexRAP knockout mice. (B) Body weight and composition of WT and
PexRAP-iKO mice at baseline and after tamoxifen treatment and HFD. (C) Oxygen consumption (VO2) by indirect
calorimetry in HFD-fed mice. Panels B-C, *P<0.05; n=4. (D) H&E staining of gWAT and BAT. (E)
Immunohistochemical analysis of UCP1 expression in iWAT. Panels F and G, adipose-specific PexRAP knockout
mice. (F) Gene expression in iWAT of WT and PexRAP-AKO mice following a 3 day cold-exposure. *P<0.05;
**P<0.01; n=3. (G) Western blot analysis of iWAT from cold-treated mice. *Non-specific band detected using the
Abcam anti-UCP1 antibody. (H) Primary iWAT stromal vascular cells from control and PexRAP-iKO mice were
treated with 3 uM 4-hydroxytamoxifen upon reaching 90% confluence. After 4 days, the cells were subjected to
brown adipogenesis and analyzed for gene expression. (I-J) Gene expression analysis and oxygen consumption rate
of PPARg-MEFs subjected to brown adipogenesis. *P<0.05; **P<0.01; ***P<0.001; n=5-6.

2.3.2 Generation of PexRAP knockout mice
To determine its role in adiposity and metabolism, PexRAP (encoded by dhrs7b) was
knocked out in mice (Figure S2.1) using a targeting vector obtained from the EUCOMM
repository (Figures S2.1A-B). The initial allele generated by this strategy is referred to as
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“knockout-first” (Skarnes et al., 2011) in which a bgal/Neo cassette disrupts expression. Mice
homozygous for the knockout-first allele manifested embryonic lethality with only a small
number of animals surviving into adulthood. Heterozygotes were viable, fertile and had no overt
phenotype. Mass spectrometric analysis of lipid extracted from the postnuclear fraction of WAT
homogenate indicated a preferential decrease in phosphatidylcholine species with arachidonic
acid at the sn-2 position of the glycerol backbone in the knockout mice (Figure S2.1C). Etherlinked phospholipids, including plasmalogens, were present in low abundance in this fraction of
the adipose tissue. The single plasmalogen species (p16:0/20:4-GPC) detected with m/z ratio of
766.6 was decreased in the knockout (Figure S2.1C).

2.3.3 PexRAP knockout mice have increased browning of subcutaneous white
adipose tissue
The surviving homozygous knockout mice were visibly smaller in size. Body weight
measured in one-month-old male knockout mice was approximately one-third less than WT mice
(Figure S2.1D). Gene expression analysis of gonadal and inguinal white adipose tissues (gWAT
and iWAT, respectively) showed depot-specific effects of the knockout (Figure S2.1E). In
gWAT, PexRAP knockout resulted in decreased expression of PPARg and its target genes. In
iWAT, PexRAP inactivation resulted in a striking increase in UCP1. PGC1a, Cidea and PPARa
messages were also increased, but PPARg expression was minimally affected in iWAT (Figure
S2.1E). Histologic analysis confirmed increased UCP1 expression in iWAT (Figure S2.1F).
Together, these results suggest that PexRAP inactivation results in browning of subcutaneous
WAT.
To study the effect on adipose tissue remodeling in detail, we converted the knockoutfirst allele into a conditional allele and crossed the floxed mice with ROSA-CreER mice to
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generate tamoxifen-inducible global PexRAP knockout (PexRAP-iKO) animals. We recently
reported that PexRAP expression was decreased in multiple tissues of tamoxifen-treated
PexRAP-iKO mice, including liver, bone marrow, and white adipose tissue, but not in the brain.
Adult PexRAP-iKO mice treated with tamoxifen survive but have leukopenia due to the nearly
complete loss of neutrophils (Lodhi et al., 2015).
Body composition analysis by EchoMRI indicated that PexRAP-iKO had significantly
reduced adiposity when subjected to high fat feeding (Figure 2.1B). The decreased adiposity
was observed despite hyperphagia (Figure S2.2A). Indirect calorimetry indicated that the
knockout mice have elevated energy expenditure (Figure 2.1C). Histologic analysis showed that
white adipocytes were smaller in PexRAP-iKO mice and brown adipocytes had marked
depletion of lipid droplets (Figure 2.1D). Morphometric analysis of the gonadal adipose depot
confirmed that adipocyte size and number were significantly decreased in PexRAP-iKO mice as
compared to control animals (Figures S2.2B-C). Immunohistologic analysis using an anti-UCP1
antibody indicated robust browning of iWAT following tamoxifen-inducible knockout of
PexRAP (Figure 2.1E). Together, these data suggest that knockout of PexRAP in precursor cells
reprograms adipose tissue development and function.
To determine if the increased browning observed with PexRAP deficiency was due to
effects intrinsic to adipose tissue, we generated adipose-specific PexRAP knockout (PexRAPAKO) mice (Figures 2.1F-G) by crossing the floxed mice with adiponectin-Cre transgenic mice
(Eguchi et al., 2011). Adipose-specific PexRAP inactivation had no effect on body weight or
body composition in mice fed chow diet or a high fat diet (not shown), perhaps suggesting that
the protein is more important during an earlier stage of fat development and less so in mature
adipose tissue. Adipose PexRAP deficiency also did not alter thermogenic gene expression at
room temperature (not shown). However, when subjected to cold exposure for three days,
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PexRAP-AKO mice manifested a 7-fold increase in UCP1 expression in iWAT. Other markers
of brown adipocytes, including Cidea and PPARa were also significantly increased (Figure
2.1F). Western blot analysis confirmed the increased UCP1 and decreased PexRAP expression in
knockout mice (Figure 2.1G).

2.3.4 Cell autonomous effect of PexRAP inactivation on thermogenic gene
expression
To determine if the effect of PexRAP inactivation on thermogenic gene expression was
cell autonomous, we collected the stromal vascular fraction from iWAT of PexRAP-iKO and
control mice and treated the cells with 4-hydroxytamoxifen (4-OHT) to knockout PexRAP.
Following differentiation of these cells using a pro-brown adipogenesis cocktail (Fisher et al.,
2012), UCP1 gene expression increased approximately 4-fold with the PexRAP inactivation
(Figure 2.1H). Knockdown of PexRAP in HIB1b brown preadipocytes (Figure S2.2D) or in
PPARg-overexpressing immortalized mouse embryonic fibroblasts (PPARg-MEFs) (Figure 2.1I)
using lentiviral shRNA, a separate approach, also strikingly increased thermogenic gene
expression. Basal and uncoupled rates of respiration were significantly increased with PexRAP
knockdown in PPARg-MEFs (Figure 2.1J), suggesting that the increase in thermogenic gene
expression is physiologically relevant. Together, these data suggest that PexRAP is a cell
autonomous regulator of UCP1 gene expression.

2.3.5 Identification of PexRAP-interacting proteins in adipocytes using SILAC
To understand the molecular mechanism of PexRAP function in adipocytes, we used
SILAC (Stable Isotope Labelling with Amino Acid of Cells in Culture), a mass spectrometrybased proteomics approach (Trinkle-Mulcahy et al., 2008), to identify PexRAP-interacting
proteins in 3T3-L1 adipocytes, using the strategy depicted in Figure 2.2A. A complete list of
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interacting proteins identified by this approach is presented in Table S2.1. Analysis of proteinprotein interactions using the STRING database (v10.0) revealed that many of the potential
PexRAP-interacting proteins interact with each other (Figure 2.2B), suggesting that some of
these were probably pulled down as components of multi-protein complexes and are not
necessarily direct binding partners of PexRAP. The interacting proteins were broadly categorized
into several functional groups, including lipid and glucose metabolism, protein translation and
targeting, and protein degradation (Figure 2.2C). The identification of proteins such as PMP70
(Abcd3), HSD17b4 (peroxisomal D-bifunctional protein) and AGPAT9 as PexRAP binding
proteins reinforced our notion that PexRAP is a peroxisomal protein involved in lipid
metabolism. The pathway of PexRAP-mediated phospholipid synthesis starts in peroxisomes and
is completed in the ER. PexRAP catalyzes the final peroxisomal step, generating
lysophosphatidic acid (LPA) or its ether lipid equivalent, 1-O-alkyl glycerol 3-phosphate (AGP)
(Lodhi and Semenkovich, 2014). The identity of proteins that catalyze the subsequent steps is
unclear. AGPAT9 is an ER-localized acyglycerolphosphate acyltransferase that might catalyze
the next step in the PexRAP pathway. We confirmed the interaction of PexRAP with AGPAT9
using GST pulldown and co-immunoprecipitation assays (Figures 2.2D-E).
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Figure 2.2. Identification of PexRAP interacting proteins by SILAC in adipocytes. (A) Strategy to identify
PexRAP interacting proteins using SILAC. (B) STRING (v10.0) analysis of the cellular proteins identified by the
SILAC approach. (C) Several different classes of PexRAP-binding proteins in adipocytes. (D) Pulldown assay of
FLAG-AGPAT9 using GST-PexRAP. *GST-PexRAP band non-specifically detected by the FLAG antibody. (E)
Co-immunoprecipitation of myc-PexRAP with FLAG-AGPAT9.
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2.3.6 Nuclear localization of PexRAP
While these interactions might be predicted, we also found unexpected potential binding
proteins. For example, identification of the interaction with importin-b1 (Kpnb1), a karyopherin
that interacts with non-classical nuclear localization sequence (NLS), was surprising and
suggested that PexRAP may also be localized in the nucleus. Sequence analysis revealed a nonclassical NLS in PexRAP similar to the importinb-interacting NLS found in parathyroid
hormone-related protein (PTHrP) (Cingolani et al., 2002) (Figure 2.3A). To determine if this
sequence is required for interaction with importin-b, we generated a DNLS mutant of PexRAP.
Although GST-tagged wild-type PexRAP interacted with importin-b, internal deletion of the
NLS completely abolished the interaction (Figure 2.3A-B). Subcellular fractionation of 3T3-L1
adipocytes indicated that PexRAP is present in the nucleus in addition to its expected enrichment
in peroxisome and membrane fractions (Figure 2.3C). Immunofluorescence analysis using an
anti-PexRAP/DHRS7b antibody in differentiated PPARg-MEFs (Figure 3D) or in U-251 MG
cells revealed punctate cytosolic staining typically observed for peroxisomal proteins as well as
nuclear staining (Figure S2.3). To determine the role of PexRAP in nuclear phospholipid
synthesis, we knocked down its expression in fully differentiated PPARg-MEFs. Mass
spectrometric analysis of lipids extracted from the nuclear fraction indicated that
phosphatidylcholine (PC) levels were significantly reduced with PexRAP knockdown (Figures
2.3E-F). Interestingly, alkyl ether-linked PCs were abundantly present in the nucleus and
reduced following PexRAP knockdown. Together, these data suggest that in addition to its
localization in peroxisomes, PexRAP is present in the nucleus and may be involved in nuclear
phospholipid synthesis.
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Figure 2.3. Nuclear localization of PexRAP. (A) Identification of a non-classical NLS in PexRAP sharing
homology with a known Importin-b1 interacting NLS identified in the PTHrP. (B) GST-pulldown of FLAG-tagged
Importin-b1 using WT and ΔNLS-PexRAP. (C) Subcellular fractionation of 3T3-L1 adipocytes. (D)
Immunofluorescence analysis using anti-PexRAP and anti-caveolin antibodies in PPARg-MEFs differentiated into
adipocytes. (E) Mass spectrometric analysis of nuclear phosphatidylcholine species in differentiated PPARg-MEFs
treated with scrambled or PexRAP shRNA. The “e” denotes ether-linked lipid species. *P<0.05; **P<0.01; n=3. (F)
Western blot analysis of PexRAP knockdown in the cells used in panel E.

2.3.7 PexRAP interacts with PRDM16 and PPARg and inhibits their
interaction with each other
Another surprise was the identification of PRDM16 as a potential PexRAP binding
protein (Figure 2.4). Because PRDM16 is expressed at very low levels in 3T3-L1 adipocytes
(Seale et al., 2007), this is likely a specific interaction. We confirmed the interaction by Western
blot analysis of tagged PRDM16 pulled down with GST-PexRAP (Figure 2.4A). Using various
GST-tagged fragments of PRDM16, we mapped a region encompassing residues 680-880 as the
site of interaction with PexRAP (Figure 2.4B). Interestingly, this is also the region of PRDM16
through which it interacts with CtBP1 to repress white adipocyte genes (Kajimura et al., 2008).
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PRDM16 regulates thermogenesis by interacting with and co-activating PPARa and
PPARg (Kajimura et al., 2009). Because PexRAP deficiency increases thermogenic gene
expression, we hypothesized that PexRAP sequesters PRDM16 away from these nuclear
receptors. While testing this possibility, we discovered that PexRAP itself directly interacts with
the ligand binding domains of PPARa and PPARg, the interaction being stronger with PPARg
than PPARa (Figure 2.4C). Given these interactions, it is possible that PexRAP may be a
transcriptional cofactor of PPARs.
Transcriptional cofactors frequently contain a leucine-rich stretch of amino acids called
the LxxLL motif (Bulynko and O'Malley, 2011; Plevin et al., 2005). This motif is involved in
interaction with the activation function-2 (AF-2) region of ligand binding domain in nuclear
receptors (Plevin et al., 2005). Sequence analysis of PexRAP revealed an LxxLL motif
(38LFRLL42 in the mouse sequence) near the N-terminus. Internal deletion of these five residues
in PexRAP abolished the interaction with PPARg (Figure 2.4D), strongly suggesting a
physiologically relevant PexRAP/PPARg interaction.
To determine if PexRAP affects the interaction of PRDM16 with PPARg, we ectopically
expressed tagged PexRAP or PRDM16 alone or together and conducted pulldown assays using
GST or GST-PPARg. When either protein was expressed alone, it interacted with PPARg.
However, when PexRAP and PRDM16 were co-expressed, PexRAP inhibited the ability of
PRDM16 to interact with PPARg (Figure 2.4E).
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Figure 2.4. PexRAP interacts with PRDM16 and PPARg and disrupts PRDM16-mediated gene expression.
(A) HA-PRDM16 pulldown using GST-PexRAP. (B) Myc-PexRAP pulldown using various GST-tagged fragments
of PRDM16. (C) Myc-PexRAP pulldown using GST-LBD of PPARa and PPARg. (D) Deletion of an LxxLL motif
in PexRAP abolishes the interaction with PPARg. (E) PexRAP competes with PRDM16 for interaction with PPARg.
(F) Fluorescence microscopy analysis of 293T cells transfected with a GFP under the control of a -5.5 kb UCP1
promoter alone or together with HA-PRDM16 and Myc-PexRAP. A schematic of the UCP1-GFP construct is
shown. (G) Western blot analysis of protein expression of 293T cells in F. (J) Oil Red O staining in BAT stromal
vascular cells differentiated into brown adipocytes following overexpression of lentiviral-encoded GFP or PexRAP.
(K) Gene expression analysis in the cells in panel J. *P<0.05; n=3.

2.3.8 PexRAP regulates PRDM16-mediated transcriptional activity
To determine whether PexRAP affects PRDM16-mediated UCP1 gene expression, we
generated a GFP reporter driven by a -5.5 Kb mouse UCP1 promoter (Figure 2.4F). Recently
ZFP516, a transcriptional activator of UCP1, was shown to drive the expression of a similar
UCP1-GFP reporter in 293FT cells (Dempersmier et al., 2015). As shown in Figure 2.4F,
overexpression of PRDM16 also strikingly promoted the expression of the UCP1-GFP in 293T
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cells. However, co-expression of PexRAP with PRDM16 markedly decreased the expression of
the reporter, suggesting that PexRAP inhibits PRDM16-mediated thermogenic gene expression
(Figure 2.4F). Western blot analysis of the overexpressed proteins is shown in Figure 2.4G.
To determine if PexRAP directly regulates recruitment of PRDM16 to brown adipocyte
genes, we performed chromatin immunoprecipitation (ChIP) assays using an anti-FLAG
antibody followed by qPCR in immortalized BAT SV cells stably expressing FLAG-PRDM16.
Whereas knockdown of PexRAP in these cells significantly increased recruitment of PRDM16 to
ppargc1a and ucp1 (Figure 2.4H), lentivirus-mediated overexpression of PexRAP markedly
decreased binding of PRDM16 to ppargc1a and modestly, but significantly decreased binding to
ucp1 (Figure 2.4I).
Next, we determined whether PexRAP overexpression affects thermogenic gene
expression in BAT SV cells isolated from wild-type mice. Although overexpression of PexRAP
in these cells following adipogenesis did not affect gene expression (Figure S2.3D), its
overexpression prior to differentiation impaired adipogenesis and reduced thermogenic gene
expression (Figures 2.4J-K). This is consistent with the possibility that PexRAP is likely
involved in an earlier step of BAT development. The inhibition of brown adipogenesis with
PexRAP overexpression suggests that the protein might have other functions independent of
directly inhibiting PRDM16 function, perhaps modulating PPARg activation.

2.4 Discussion
Since beige fat might counteract obesity, adipose tissue remodeling has drawn
considerable interest. Several factors have been identified that promote brown adipogenic
programs, including PRDM16 and Ebf2 (Cohen et al., 2014; Harms et al., 2014; Rajakumari et
al., 2013). Similarly, other factors have also been identified that inhibit brown and beige
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adipogenesis, including Rb/p107, MRTFA, TLE3, and Zfp423 (De Sousa et al., 2014; Hansen et
al., 2004; McDonald et al., 2015; Shao et al., 2016; Villanueva et al., 2013). Previously, we
identified PexRAP as a peroxisomal lipid synthetic enzyme that regulates adipogenesis (Lodhi et
al., 2012). Here, we present evidence suggesting that PexRAP is a dual function regulator of
adipose tissue remodeling that inhibits thermogenic gene expression. Although PexRAP is
abundantly present in WAT, PexRAP protein levels are very low in mature BAT. Inactivation of
PexRAP in mice results in robust browning of subcutaneous white fat. Identification of PexRAP
interacting proteins and characterization of its subcellular localization suggest that in addition to
its role as a peroxisomal lipid synthetic enzyme, PexRAP is found in the nucleus, where it affects
transcriptional regulation of adipose tissue browning. Together, these studies suggest that
PexRAP might be part of a previously unrecognized peroxisome-to-nucleus regulatory circuit
that controls adipose tissue remodeling.
PexRAP possesses a cryptic non-classical nuclear localization sequence through which it
interacts with importin-b1. It is unclear whether PexRAP translocates from peroxisomes to the
nucleus in response to a physiological stimulus or if there is a constitutively localized pool of
PexRAP in the nucleus. There is precedent for transmembrane protein translocation to the
nucleus in response to stimuli. For example, AEG-1 (astrocyte elevated gene-1), an ER-localized
transmembrane protein, translocates to the nucleus in response to TNFa treatment and functions
as a transcriptional co-activator of NFkB (Sarkar et al., 2008).
Our results suggest that nuclear localized PexRAP interacts with PRDM16 as well as
PPARg and prevents their interaction with each other, which could be the mechanism underlying
the inhibitory role of PexRAP in adipocyte browning. Consistent with this notion, PexRAP
overexpression inhibited PRDM16-mediated thermogenic gene expression and impaired brown
adipogenesis.
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A similar mechanism of action has been proposed for TLE3, a white-selective
transcriptional regulator that inhibits brown adipocyte-selective gene expression by disrupting
the interaction between PRDM16 and PPARγ (Villanueva et al., 2013). Moreover, the
transcriptional regulator ZFP423 was recently shown to be important for maintaining white
adipocyte identity by inhibiting thermogenic gene expression mediated by the brown-selective
transcription factor Ebf2 (Shao et al., 2016). The need for seemingly redundant mechanisms for
regulating adipose tissue remodeling remains unexplained. Perhaps these transcriptional
regulators assume stage-specific roles during discrete steps in adipose tissue development. For
example, Zfp423 is thought to function primarily at the level of mature white adipocyte to inhibit
thermogenic gene expression (Shao et al., 2016). Our studies suggest that PexRAP is likely more
important during an earlier step of fat development. Notably, although ZFP423 can directly bind
to DNA and regulate transcription, TLE3 and PexRAP lack DNA binding domains and regulate
transcription through their ability to interact with other transcription factors. TLE3 and PexRAP
both interact with PPARg, but PexRAP is unique in also possessing lipid synthetic activity that
generates ether-linked phospholipids, potential partial agonists of PPARg (Lodhi et al., 2012).
Although PPARg could be activated by several different lipid ligands with variable
effects on transcriptional activity, it is likely that the endogenous agonists of PPARg in general
are partial agonists that promote recruitment of distinct transcriptional cofactors controlling
unique subsets of genes. This could be the mechanism allowing PPARg to regulate the
development of two functionally distinct types of adipose tissue, as well as the browning of
WAT. In addition to the peroxisome-derived phospholipids that we identified, LPA and AGP,
both products of PexRAP (Lodhi et al., 2012), have been reported to activate PPARg (McIntyre
et al., 2003; Stapleton et al., 2011; Tsukahara et al., 2006). The nuclear localization of PexRAP
and its association with PPARg suggest that PexRAP might locally generate these lipid agonists,
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thus increasing efficacy and availability to PPARg. Our results presented here and those of others
(Albi and Viola Magni, 2004) suggest that ether lipids, including plasmalogens, are abundantly
present in the nucleus.
PexRAP possesses transcriptional regulatory activity that extends beyond its established
role as a peroxisomal lipid synthetic enzyme, suggesting a multifaceted role for the protein in
adipose tissue remodeling. Pharmacological inhibition of PexRAP function in adipose tissue may
be an appropriate strategy for treating obesity.

2.5 Experimental Procedures
2.5.1 RT-PCR
Total RNA was extracted using PureLink RNA kit (Invitrogen) and reverse transcribed
using High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative PCR
was performed with an Applied Biosystems StepOne Plus instrument using PowerUP SYBR®
Green reagent (Applied Biosystems). Pre-validated primers spanning exon-exon boundaries were
used for amplifications. Assays were performed in duplicate and results were normalized to
ribosomal protein L32 mRNA levels, which were unaffected by genotype or intervention.

2.5.2 Pulldown Assays
GST-pulldown assays were performed as previously described (Lodhi et al., 2012).
Briefly, cells were lysed using a buffer containing 50 mM HEPES (pH 7.4), 4 mM EDTA, 2 mM
EGTA, 2 mM sodium pyrophosphate, 1% Triton X-100, 10 mM NaF, and protease inhibitors
(Sigma P8340). Cell lysates were mixed with an equal volume of the same buffer containing no
Triton x-100, then 5ug of GST alone beads or GST fusion protein beads and rocked at 4C for 2h.
Samples were spun down at 2500g x 1 min and washed 5x with lysis buffer containing 0.5%
Triton X-100 before being resuspended in SDS sample buffer and subjected to SDS-PAGE.
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2.5.3 Measurement of Oxygen Consumption Rate in Adipocytes
Oxygen consumption rate (OCR) in PPARγ-MEFs was measured using XF24
Extracellular Flux Analyzer with a FluxPak provided by Seahorse Bioscience. The cells were
seeded and grown to confluence on XF24 cell culture microplates, followed by infection with
lentiviral-encoded scrambled or PexRAP shRNA. Eight days after the infection, the cells were
exposed to browning cocktail to induce brown adipocyte differentiation for 6 days. OCR was
measured at 3-min intervals at baseline and after the addition of oligomycin (3 µM final
concentration).

2.5.4 UCP1-GFP Reporter Assay
To construct the UCP1-GFP reporter construct, a -5.5kb UCP1 promoter was amplified
by PCR using liver genomic DNA from a wild-type C57 mouse and cloned into the pCMV6-ACGFP plasmid in place of the CMV promoter. HEK293T cells were grown on poly-l-lysine coated
coverslips and transfected with either UCP1-GFP or UCP1-GFP and HA-PRDM16, or UCP1GFP, HA-PRDM16, and Myc-PexRAP. Following 3 days after transfection, coverslips were
mounted and imaged with a Leica DMI4000B inverted fluorescence microscope.

2.5.5 Cell Culture and Adipocyte Differentiation
Human embryonic kidney 293T (HEK293T) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% FBS. Intrascapular BAT was
collected from postnatal day 1 pups of wild-type C57 mice and brown preadipocytes were
isolated by collagenase and dispase digestion as previously described (Klein et al., 2002; Uldry
et al., 2006). The cells were immortalized by infection with a retrovirus expressing large Tantigen (pBABE-neo largeTcDNA; Addgene #1780) (Hahn et al., 2002) and selected using G418
selection (50 ug/ml) after 4 days. Brown adipocyte differentiation was induced as described
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previously (Uldry et al., 2006). Briefly, confluent cells were treated with DMEM/F12
supplemented with 0.5 uM isobutylmethylxanthine, 5uM dexamethasone, 125uM indomethacin,
1 uM rosiglitazone, 1 nM T3, and 0.02 uM insulin. After two days, the cells were switched to
media supplemented only with 1 nM T3 and 0.02 uM insulin. The media was changed every 2
days.
Stromal vascular fraction from mouse WAT was isolated and differentiated into
adipocytes as previously described (Fisher et al., 2012; Ohno et al., 2012). MEFs overexpressing
PPARγ, a generous gift of Dr. Charles Harris (Washington University), were maintained in
DMEM supplemented with 10% FBS. To induce beige adipocyte differentiation, the MEFs were
grown to confluence and treated with brown adipogenesis induction cocktail consisting of 5 µM
dexamethasone, 0.5 uM isobutylmethylxanthine, 0.02 µM insulin, 1 nM T3, 125 µM
indomethacin, and 1 µM rosiglitazone in DMEM/F12 complete medium. Three days after the
induction, cells were exposed to the brown adipogenesis maintenance cocktail composed of 0.02
µM insulin, 1 nM T3, and 1 µM rosiglitazone in DMEM/F12 complete medium. The cells were
harvested for analyses on day 7 after the start of differentiation. 3T3-L1 cells were maintained
and differentiated into adipocytes as previously described (Lodhi et al., 2012).

2.5.6 Animals
PexRAP (dhrs7b) knockout-first mice were generated using a targeting vector obtained
from the EUCOMM repository. Generation of tamoxifen-inducible global PexRAP knockout
(PexRAP-iKO) mice has been previously described (Lodhi et al., 2015). To induce knockout, ten
to twelve-week-old control (floxed without Cre) and PexRAP-iKO mice were treated daily with
tamoxifen (50 ug/g body weight) for 5 consecutive days. To generate adipose-specific PexRAP
knockout (PexRAP-AKO) mice with a floxed PexRAP locus (PexRAPlox/lox) were crossed with
transgenic mice expressing Cre under the control of the adiponectin promoter. Genotyping was
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performed using previously described primer sets (Lodhi et al., 2015) and diets included PicoLab
Rodent Diet 20 control chow and Harlan Teklad TD 88137 high fat diet. All protocols were
approved by the Washington University Animal Studies Committee.

2.5.7 Plasmids
PexRAP lentiviral overexpression plasmid was generated by replacing eGFP with
PexRAP in pLJM1-eGFP (Addgene #19319) (Sancak et al., 2008). MSCV-FLAG-PRDM16
(#15504) (Seale et al., 2007) and GST-tagged fragments of PRDM16 (#53346-51) were obtained
from Addgene. PexRAP shRNA lentivirus, as well as GST-tagged PexRAP, PPARg and PPARa
plasmids were previously described (Lodhi et al., 2012). GST-PexRAPDNLS and MycPexRAPDLxxLL were created by deleting of the indicated region via site-directed mutagenesis
using QuikChange II XL kit (Agilent Technologies). For transient expression, PexRAP and
PRMD16 were cloned into pRK5-myc and pKH3-HA vectors, respectively. FLAG-Importinb1
was purchased from Genscript. UCP1-GFP reporter construct was created by amplifying the 5.5kb UCP1 promoter region from liver genomic DNA from a wild-type C57 mouse and cloned
into the pCMV6-AC-GFP plasmid in place of the CMV promoter.

2.5.8 Antibodies
Rabbit polyclonal antibodies against actin and PexRAP (DHRS7b), and mouse
monoclonal antibodies against PMP70 and FLAG (M2) were from Sigma (St. Louis, MO).
Polyclonal anti-UCP1 antibody used for immunocytochemistry was from Abcam (Cambridge,
MA). The UCP1 antibody used for Western blotting was from Alpha Diagnostics (San Antonio,
TX). Antibodies against HA, Myc and b-tubulin were from Santa Cruz Biotechnology (Santa
Cruz, CA). Rabbit polyclonal antibodies against Lamin A/C and Akt were from Cell Signaling
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Technology (Danvers, MA). Light chain-specific HRP-conjugated secondary antibody was from
Jackson ImmunoResearch (West Grove, PA).

2.5.9 SILAC
3T3-L1 cells cultured for 4 passages in media containing “heavy” 13C6 L-lysine and
13C6 L-arginine or light L-12C6 L-lysine and 12C6 L-arginine were differentiated into
adipocytes and lysed using a buffer containing 1% Triton- X-100. The “heavy” lysates were
subjected to pulldown using GST-PexRAP and an equal amount of “light” lysates were subjected
to pulldown using GST alone. Following SDS-PAGE, elution of proteins from the gel and tryptic
digest, LC-MS/MS analysis was conducted. The peptide peaks of the differentially labeled
samples were quantified relative to each other to determine the peptide and protein ratios.
Selected proteins with “heavy” to “light” ratios greater than 2 were chosen for further study. A
number of proteins with a heavy/light ratio greater than 2 were deemed low probability targets
and omitted from the analysis because they have been shown to be ubiquitous bead proteome
interactors. These include ribosome related proteins, translation initiation factors, DNA/RNA
helicases, cytoskeletal proteins, and heat shock proteins (Trinkle-Mulcahy et al., 2008). STRING
program (version 10.0) was used to analyze protein-protein interactions and to group interactors
into functional classes (Szklarczyk et al., 2015).

2.5.10 Lipid Analysis by Mass Spectrometry
Lipids were extracted from adipocytes as previously described (Bligh and Dyer, 1959)
and analyzed by mass spectrometry. Low-energy CAD tandem mass spectrometry was
conducted on a Thermo Scientific (San Jose, CA) TSQ Vantage Triple Stage Quadrupole mass
spectrometer equipped with Xcalibur operating system as described (Hsu et al., 2014).
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2.5.11 Subcellular fractionation
Subcellular fractionation of adipocytes was conducted as previously described (Cai et al.,
2006). Fractions enriched in peroxisomes were isolated from adipocytes using the Peroxisome
Isolation Kit (Sigma), as previously described (Lodhi et al., 2012).

2.5.12 Chromatin Immunoprecipitation (ChIP)
ChIP studies were conducted using the SimpleChIP Enzymatic Chromatin IP Kit (Cell
Signaling Technology) according to manufacturer’s instruction. Briefly, BAT SV stably
expressing FLAG-tagged PRM16 and over expressing either GFP or PexRAP were fixed with
1% formaldehyde for 15 mins. Nuclei were harvested and chromatin digested by micrococcal
nuclease before being lysed on ice by 3 sets of 10-second pulses from a Sonics VCX 500 probe
sonicator at 30% amplitude. Chromatin was clarified by centrifugation before being incubated
with normal rabbit IgG, Histone H3, or FLAG M2 (Sigma F1804) antibodies at 4C overnight.
ChIP-Grade protein G agarose beads were incubated for 4 hours, spun, and washed. Crosslinks
were reversed and DNA was purified by spin column. DNA was quantified by qPCR using
PowerUp Sybr Green Master Mix (Thermo Fisher) in triplicate and data are shown as percentage
of input. Primer sequences used in qPCR are as described previously (Harms et al., 2015).

2.5.13 Statistics
Results are expressed as means ± SEM. Comparisons between two groups were
performed using two-tailed Student’s t test. One-way ANOVA with Tukey’s posttest was used
for comparison of more than two groups. P values <0.05 was considered to denote statistically
significant differences.
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2.6 Supplemental Information
2.6.1 Supplemental Figures

Figure S2.1 Generation and characterization of PexRAP knockout -first mice, related to Figure 2.1. (A) Effect
of 1-week cold exposure on PexRAP protein levels in iWAT. Each lane represents a separate mouse. B) Gene
targeting strategy for the generation of PexRAP knockout mice. (C) Genotyping results using primers flanking the
second LoxP site. (D) Mass spectrometric analysis of phosphatidylcholine species in the gWAT postnuclear fraction
of WT and KO mice, with decreased lipids indicated in red font. (E) Body weight of WT and PexRAP KO mice at 1
month of age. *P<0.05; n=3. (F) Gene expression analysis in gWAT and iWAT. Data are presented as mean ± SEM
and are representative of 3 mice per group. *P<0.05. (G) Immunohistochemical analysis of UCP1 expression in the
iWAT of WT and KO mice.
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Figure S2.2 Characterization of PexRAP-iKO mice and the effect of PexRAP knockdown on UCP1 gene
expression in HIB1b cells, related to Figure 1. (A) Average daily food intake of HFD-fed mice. (B-C) Adipocyte
size and number in gWAT of PexRAP-iKO and control mice. (D) Lentiviral shRNA-mediated knockdown of
PexRAP in HIB1b cells increases UCP1 gene expression. *p<0.05.
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Figure S2.3 Western blot analysis of PRDM16 and PexRAP and the effect of PexRAP overexpression on gene
expression in BAT SV cells, related to Figure 4. (A) Immortalized BAT SV cells were transduced with a control
retrovirus or a retrovirus encoding FLAG-PRDM16. The level of PRDM16 overexpression was assessed by Western
blotting using anti-FLAG and PRDM16 antibodies. (B-C) FLAG-PRDM16 overexpressing BAT SV cells were
treated with scrambled or PexRAP shRNA (B) or with lentivirus expressing GFP or PexRAP (C). Following
treatment with a brown adipogenesis cocktail for 2 days, Western blot analysis was performed using an antiPexRAP antibody. (D) Wild-type BAT SV cells were differentiated to adipocytes and then treated with lentivirus
expressing GFP or PexRAP. Gene expression analysis was conducted at day 4 after lentiviral infection. *P<0.05;
n=3.
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2.6.2 Supplemental Tables
Table S2.1 PexRAP Interacting Proteins Identified Using SILAC, Related to Figure 2.2
Symbol

Description

H:L
Ratio
7.44

#
of
Peptides
7

ABCD3_MOUSE

ATP-binding cassette sub-family D member 3 OS=Mus musculus
GN=Abcd3=PMP70 PE=1 SV=1
Acyl-CoA dehydrogenase family member 9, mitochondrial
OS=Mus musculus GN=Acad9 PE=2 SV=1
Acyl-CoA desaturase 1 OS=Mus musculus GN=Scd1 PE=1 SV=2

6.46

3

7.38

2

Long-chain-fatty-acid--CoA ligase 1 OS=Mus musculus GN=Acsl1
PE=1 SV=1
Chaperone activity of bc1 complex-like, mitochondrial OS=Mus
musculus GN=Adck3 PE=2 SV=2
ADP/ATP translocase 2 OS=Mus musculus GN=Slc25a5 PE=1
SV=3
Apoptosis-inducing factor 1, mitochondrial OS=Mus musculus
GN=Aifm1 PE=1 SV=1
Acidic leucine-rich nuclear phosphoprotein 32 family member A
OS=Mus musculus GN=Anp32a PE=1 SV=1
Acidic leucine-rich nuclear phosphoprotein 32 family member B
OS=Mus musculus GN=Anp32b PE=1 SV=1
ADP-ribosylation factor 5 OS=Mus musculus GN=Arf5 PE=2
SV=2
Aspartyl/asparaginyl
beta-hydroxylase
OS=Mus
musculus
GN=Asph PE=2 SV=1
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Mus
musculus GN=Atp2a2 PE=1 SV=2
ATPase family AAA domain-containing protein 3 OS=Mus
musculus GN=Atad3 PE=1 SV=1
ATG5-autophagy

5.89

2

17.02

3

5.02

16

9.68

12

21.7

6

39.23

8

18.96

3

4.39

6

16.9

17

3.07

2

2.43

3

musculus

8.41

30

musculus

4.35

3

musculus

9.42

11

musculus

3.22

2

CALR_MOUSE

ATP synthase subunit alpha, mitochondrial OS=Mus
GN=Atp5a1 PE=1 SV=1
ATP synthase subunit beta, mitochondrial OS=Mus
GN=Atp5b PE=1 SV=2
ATP synthase subunit gamma, mitochondrial OS=Mus
GN=Atp5c1 PE=1 SV=1
ATP synthase subunit O, mitochondrial OS=Mus
GN=Atp5o PE=1 SV=1
Calreticulin OS=Mus musculus GN=Calr PE=1 SV=1

22.7

4

CALU_MOUSE

Calumenin OS=Mus musculus GN=Calu PE=1 SV=1

23.9

10

CE290_MOUSE

12.45

2

COPB_MOUSE

Centrosomal protein of 290 kDa OS=Mus musculus GN=Cep290
PE=1 SV=2
Coatomer subunit beta OS=Mus musculus GN=Copb1 PE=1 SV=1

25.1

15

COPB2_MOUSE

Coatomer subunit beta' OS=Mus musculus GN=Copb2 PE=2 SV=2

13.65

15

COPE_MOUSE

Coatomer subunit epsilon OS=Mus musculus GN=Cope PE=2
SV=3
Coatomer subunit gamma OS=Mus musculus GN=Copg PE=2
SV=1

12.63

2

19.55

9

ACAD9_MOUSE
ACOD1_MOUSE
ACSL1_MOUSE
ADCK3_MOUSE
ADT2_MOUSE
AIFM1_MOUSE
AN32A_MOUSE
AN32B_MOUSE
ARF5_MOUSE
ASPH_MOUSE
AT2A2_MOUSE
ATAD3_MOUSE
ATG5_MOUSE
ATPA_MOUSE
ATPB_MOUSE
ATPG_MOUSE
ATPO_MOUSE

COPG_MOUSE
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COPG2_MOUSE
DECR_MOUSE
DGAT1_MOUSE
DHB12_MOUSE
DHB4_MOUSE
DLDH_MOUSE
ECHA_MOUSE
ECHB_MOUSE
EHD2_MOUSE
GANAB_MOUSE
GFPT1_MOUSE
GLU2B_MOUSE
GPAT3_MOUSE
HAX1_MOUSE
HXK2_MOUSE
IMB1_MOUSE
K6PL_MOUSE
K6PP_MOUSE
KPYM_MOUSE
LETM1_MOUSE
LIPL_MOUSE
LRC59_MOUSE
LYRIC_MOUSE
MIRO1_MOUSE
MOGS_MOUSE
MPCP_MOUSE
NP1L1_MOUSE
NPM_MOUSE
ODBB_MOUSE

Coatomer subunit gamma-2 OS=Mus musculus GN=Copg2 PE=2
SV=1
2,4-dienoyl-CoA reductase, mitochondrial OS=Mus musculus
GN=Decr1 PE=1 SV=1
Diacylglycerol O-acyltransferase 1 OS=Mus musculus GN=Dgat1
PE=1 SV=1
Estradiol 17-beta-dehydrogenase 12 OS=Mus musculus
GN=Hsd17b12 PE=2 SV=1
Peroxisomal multifunctional enzyme type 2 OS=Mus musculus
GN=Hsd17b4 PE=1 SV=3
Dihydrolipoyl dehydrogenase, mitochondrial OS=Mus musculus
GN=Dld PE=1 SV=2
Trifunctional enzyme subunit alpha, mitochondrial OS=Mus
musculus GN=Hadha PE=1 SV=1
Trifunctional enzyme subunit beta, mitochondrial OS=Mus
musculus GN=Hadhb PE=1 SV=1
EH domain-containing protein 2 OS=Mus musculus GN=Ehd2
PE=1 SV=1
Neutral alpha-glucosidase AB OS=Mus musculus GN=Ganab PE=1
SV=1
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]
1 OS=Mus musculus GN=Gfpt1 PE=1 SV=3
Glucosidase 2 subunit beta OS=Mus musculus GN=Prkcsh PE=1
SV=1
Glycerol-3-phosphate acyltransferase 3 OS=Mus musculus
GN=Agpat9 PE=1 SV=1
HCLS1-associated protein X-1 OS=Mus musculus GN=Hax1 PE=1
SV=1
Hexokinase-2 OS=Mus musculus GN=Hk2 PE=1 SV=1

46.44

2

3.18

10

7.15

1

6.63

17

2.18

2

3.12

2

11.19

27

9.34

8

16.17

6

14.31

18

18.69

6

17.78

3

6.67

2

61.6

5

3.11

3

Importin subunit beta-1 OS=Mus musculus GN=Kpnb1 PE=1
SV=1
6-phosphofructokinase, liver type OS=Mus musculus GN=Pfkl
PE=1 SV=3
6-phosphofructokinase type C OS=Mus musculus GN=Pfkp PE=1
SV=1
Pyruvate kinase isozymes M1/M2 OS=Mus musculus GN=Pkm2
PE=1 SV=4
LETM1 and EF-hand domain-containing protein 1, mitochondrial
OS=Mus musculus GN=Letm1 PE=2 SV=1
Lipoprotein lipase OS=Mus musculus GN=Lpl PE=1 SV=2

14.51

6

10.2

3

8.39

1

10.58

1

4.75

4

9.98

15

Leucine-rich repeat-containing protein 59 OS=Mus musculus
GN=Lrrc59 PE=2 SV=1
Protein LYRIC OS=Mus musculus GN=Mtdh PE=1 SV=1

3.03

11

2.49

5

Mitochondrial Rho GTPase 1 OS=Mus musculus GN=Rhot1 PE=2
SV=1
Mannosyl-oligosaccharide
glucosidase
OS=Mus
musculus
GN=Mogs PE=2 SV=1
Phosphate carrier protein, mitochondrial OS=Mus musculus
GN=Slc25a3 PE=1 SV=1
Nucleosome assembly protein 1-like 1 OS=Mus musculus
GN=Nap1l1 PE=1 SV=2
Nucleophosmin OS=Mus musculus GN=Npm1 PE=1 SV=1

11.64

2

3.35

6

12.16

4

17.41

2

5.92

10

2-oxoisovalerate dehydrogenase subunit beta,
OS=Mus musculus GN=Bckdhb PE=2 SV=2

6.17

4
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mitochondrial

OST48_MOUSE

7.69

6

4.11

3

7.92

5

2.69

4

PHB_MOUSE

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48
kDa subunit OS=Mus musculus GN=Ddost PE=1 SV=1
Proliferation-associated protein 2G4 OS=Mus musculus GN=Pa2g4
PE=1 SV=3
Plasminogen activator inhibitor 1 RNA-binding protein OS=Mus
musculus GN=Serbp1 PE=1 SV=2
Serine/threonine-protein phosphatase PGAM5, mitochondrial
OS=Mus musculus GN=Pgam5 PE=2 SV=1
Prohibitin OS=Mus musculus GN=Phb PE=1 SV=1

7.79

10

PHB2_MOUSE

Prohibitin-2 OS=Mus musculus GN=Phb2 PE=1 SV=1

7.29

13

PLIN1_MOUSE

Perilipin-1 OS=Mus musculus GN=Plin1 PE=1 SV=2

9.37

2

PRD16_MOUSE

3.67

2

5.57

3

10.37

2

20.83

3

RCN1_MOUSE

PR domain zinc finger protein 16 OS=Mus musculus GN=Prdm16
PE=1 SV=1
Protein kinase C delta-binding protein OS=Mus musculus
GN=Prkcdbp PE=1 SV=1
26S protease regulatory subunit 8 OS=Mus musculus GN=Psmc5
PE=1 SV=1
26S proteasome non-ATPase regulatory subunit 2 OS=Mus
musculus GN=Psmd2 PE=1 SV=1
Reticulocalbin-1 OS=Mus musculus GN=Rcn1 PE=1 SV=1

16.52

4

RCN2_MOUSE

Reticulocalbin-2 OS=Mus musculus GN=Rcn2 PE=2 SV=1

19.94

15

RPN1_MOUSE

5.29

2

9.45

4

11.17

6

SE1L1_MOUSE

Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase
subunit 1 OS=Mus musculus GN=Rpn1 PE=2 SV=1
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase
subunit 2 OS=Mus musculus GN=Rpn2 PE=2 SV=1
Protein transport protein Sec61 subunit alpha isoform 1 OS=Mus
musculus GN=Sec61a1 PE=2 SV=2
Protein sel-1 homolog 1 OS=Mus musculus GN=Sel1l PE=2 SV=2

32.4

2

SET_MOUSE

Protein SET OS=Mus musculus GN=Set PE=1 SV=1

16.92

3

SFPQ_MOUSE

Splicing factor, proline- and glutamine-rich OS=Mus musculus
GN=Sfpq PE=1 SV=1
Sphingosine-1-phosphate lyase 1 OS=Mus musculus GN=Sgpl1
PE=2 SV=1
Translocon-associated protein subunit alpha OS=Mus musculus
GN=Ssr1 PE=1 SV=1
Translocon-associated protein subunit delta OS=Mus musculus
GN=Ssr4 PE=2 SV=1
Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial
OS=Mus musculus GN=Suclg1 PE=1 SV=4
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial
OS=Mus musculus GN=Suclg2 PE=2 SV=3
Methionyl-tRNA synthetase, cytoplasmic OS=Mus musculus
GN=Mars PE=2 SV=1
Transducin beta-like protein 2 OS=Mus musculus GN=Tbl2 PE=2
SV=1
Transitional endoplasmic reticulum ATPase OS=Mus musculus
GN=Vcp PE=1 SV=4
Mitochondrial import inner membrane translocase subunit TIM50
OS=Mus musculus GN=Timm50 PE=1 SV=1
General vesicular transport factor p115 OS=Mus musculus
GN=Uso1 PE=1 SV=2

4.16

3

3.84

3

10.59

3

11.38

4

6.63

2

7.52

2

13

4

3.36

2

12.06

21

9.49

3

14.1

6

PA2G4_MOUSE
PAIRB_MOUSE
PGAM5_MOUSE

PRDBP_MOUSE
PRS8_MOUSE
PSMD2_MOUSE

RPN2_MOUSE
S61A1_MOUSE

SGPL1_MOUSE
SSRA_MOUSE
SSRD_MOUSE
SUCA_MOUSE
SUCB2_MOUSE
SYMC_MOUSE
TBL2_MOUSE
TERA_MOUSE
TIM50_MOUSE
USO1_MOUSE
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Chapter 3: The Mediator Protein Med19 is
Essential for White Adipose Tissue
Development and Maintenance
Preface
The following work was written by myself. An adaptation of this chapter is currently
being written for peer-reviewed publication.
J.M.D. Conceived hypotheses, conducted experiments, interpreted data, and wrote the
manuscript. I.J.L conceived hypotheses, interpreted data, and wrote the manuscript. J.W.
performed the HOMER analysis. This work was supported by NIH grants RO1 DK115867 and
RO1 DK118333.
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3.1 Abstract
Targeting adipose tissue function to decrease adiposity and improve insulin sensitivity
could treat obesity and diabetes. An array of proteins has been implicated in the development and
maintenance of two functionally distinct types of adipose tissue, brown (BAT) and white (WAT)
fat, as well as the browning of white fat, but our understanding of these processes remains
unclear. Previously, we identified the peroxisomal, lipid synthetic enzyme PexRAP as a
transcriptional regulator of adipose tissue remodeling that inhibits thermogenic gene expression.
We discovered that PexRAP interacts with Med19 subunit of the Mediator complex, a multisubunit complex that acts as a bridge between gene-specific transcription factors and the basal
transcription machinery. Many of the specific roles of Mediator subunits, including Med19,
remain unknown.
Here, we demonstrate that Med19 plays a critical role in the development and
maintenance of white fat both in vitro and in vivo, but it is dispensable for brown fat
development. Lentivirus-mediated knockdown of Med19 in iWAT SV cells inhibited
adipogenesis. However, Med19 knockdown in brown adipocytes had no effect on adipogenesis
and appeared to increase thermogenic gene expression. Adipose-specific deletion of Med19
(Med19-AKO) in mice resulted in near ablation of WAT leading to hepatic insulin resistance and
steatosis. BAT mass was unaffected, but Med19-AKO mice manifested a significant whitening
of the thermogenic fat, most likely due to a secondary lipid “spillover” effect caused by white
adipose lipodystrophy. To study the effect of Med19 KO in mature adipose tissue, we created an
adipose-specific, tamoxifen-inducible Med19 knockout (Med19-iAKO) mouse line, which
possessed a similar phenotype to Med19-AKO animals. RNA-seq analysis of Med19-iAKO
gWAT painted a picture of an unhealthy tissue struggling to maintain adipose-specific gene
expression, resulting in loss of adipose tissue, likely due to the upregulation of genes involved in
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apoptosis, necroptosis, and inflammation. Chromatin immunoprecipitation (ChIP) in iWAT SV
cells indicated that the decrease in adipose-specific gene expression in Med19-iAKO gWAT is
likely due to reduced residency of PPARg on adipose-specific target genes. These results identify
Med19 as a crucial facilitator of PPARg-mediated gene expression that is selectively required for
the development and maintenance of WAT.

3.2 Introduction
Adipose tissue has emerged as a complex metabolic organ with a variety of functions.
Two major types of adipose tissue are found in mammals: white fat (WAT) and brown fat
(BAT). WAT primarily stores energy. In the context of obesity WAT dramatically expands to
store excess calories contributing to pathological consequences. Alternatively, BAT dissipates
energy in the form of heat and is related to positive metabolic outcomes. Another type of fat,
called beige fat, can form in subcutaneous WAT in response to cold and beta adrenergic
signaling. Adipose is a dynamic tissue that has the ability to expand, contract, and beige in
response to external stimuli. Adipocyte differentiation is the result of a complex transcriptional
cascade of adipogenic factors. PPARg, regarded as the master regulator of adipogenesis, plays a
large role in this process, conducting the expression of various other transcription factors and
proteins to ensure that adipocyte differentiation is completed, yet how PPARg regulates the
development of two functionally distinct types of adipose tissue as well as the browning of white
fat, remains unclear. Previous work in our lab contributed to this knowledge gap by showing that
the peroxisomal lipid synthetic enzyme, PexRAP, acts as a transcriptional regulator of adipose
tissue gene expression by preventing the interaction of PPARg with PRDM16 and inhibiting
PRDM16-mediated thermogenic gene expression (Lodhi et al., 2017). In doing so, we found that
PexRAP may interact with the Mediator subunit Med19 (Stelzl et al., 2005 and Supplmental
52

Figure 3.1A-B), suggesting the possibility that Med19 could be involved in adipocyte gene
expression.
The Mediator complex, composed of more than 30 subunits, acts as a bridge between
gene-specific transcription factors and the basal transcription machinery. The subunit
composition of the Mediator can vary, and different subunits interact with different transcription
factors in a cell context-dependent manner. Overall, very little is known about how this process
is regulated or about the specific function of the individual subunits (Allen and Taatjes, 2015).
Despite this, many mediator components have been implicated in adipogenesis and adipocyte
gene expression (Zhang et al., 2013). In particular, Med1 is important for white adipogenesis
through interactions with PPARg (Ge et al., 2002, 2008a), a process which is facilitated by
Med14 (Grontved et al., 2010). Med1 also plays a role in brown fat-specific gene expression by
facilitating recruitment of PRDM16 to the UCP1 enhancer (Chen et al., 2009; Iida et al., 2015).
Med23 is necessary for hormone-induced adipogenesis by facilitating the expression of the early
adipogenesis transcription factor Krox20 (Wang et al., 2009), as well as playing a critical role in
controlling the cell fate preference directing differentiation of smooth muscle cells or adipocytes
(Yin et al., 2012). Med17 is required for the transcriptional activation of lipogenic genes in
response to insulin (Viscarra et al., 2017). However, little is known about the function of Med19.
In mammals some studies have implicated Med19 as a facilitator of REST-imposed neuronal
gene silencing (Ding et al., 2009), as well as roles in cancer metastasis (He et al., 2016; Liu et al.,
2018; Wen et al., 2013). Here, we identify a new role for Med19 as a key player in white adipose
tissue development and maintenance.
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3.3 Results
3.3.1 Generation of Adipose-specific Med19 Knockout Mice
To investigate the role of Med19 in adipose tissue, we obtained mice with conditionalpotential allele of Med19 (Med19tm1a(EUCOMM)Wtsi) from the EUCOMM repository and
crossed them with actin-Flp transgenic mice to remove the targeting cassette and then
subsequently crossed the mice with adiponectin-Cre mice to generate novel adipose-specific
Med19 knockout (Med19-AKO) mice (Figures 3.1A and 3.1B). The resulting Med19-AKO
mice were overtly normal and fertile. Quantitative real-time PCR and western blot analyses
showed that Med19 RNA and protein was substantially reduced in the gWAT, iWAT, and BAT
but not the liver of Med19-AKO mice (Figures 3.1C and 3.1D).
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Figure 3.1 Lipoatrophy of white adipose tissue in Med19 adipose-specific knockout (Med19-AKO) mice. A)
Schematic of Med19 gene targeting strategy. C57 mice heterozygous for a KO-first Med19 allele were obtained
from the EUCOMM repository and crossed with transgenic mice expressing Flp recombinase to remove the
neomycin selection cassette resulting in a traditional floxed allele. These mice were subsequently crossed with mice
expressing adiponectin-cre resulting in adipose specific deletion of Med19. B) Genotyping of Med19
heterozygous floxed, wild-type, and Med19 homozygous floxed mice. C) Western blot with Med19 antibody in
adipose tissue depots of Med19-AKO and WT mice. D) qPCR analysis of Med19 expression in adipose tissue
depots and liver of Med19-AKO and WT animals. n = 5-7. E) Body weight (n = 9-14) and body composition
analysis by EchoMRI (n = 7-8) of Med19-AKO mice. F) Tissue weight of Liver, gWAT, iWAT, and BAT. n = 7-10
G) Gross images of iWAT and gWAT from WT and Med19-AKO mice. H) H&E stained histology sections
from iWAT and gWAT. Scale bar = 75um. I) qPCR analysis of gWAT tissue. n = 5-7. J) qPCR analysis
of iWAT tissue. n = 5-7 **p < 0.005, ***p < 0.0005. The results are presented as mean ± SEM. All experiments
are done in 12-16-week-old mice.
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3.3.2 Lipoatrophy of White Adipose Tissue in Med19-AKO Mice.
Although 8-week old Med19-AKO mice were the same weight as their control
littermates, 12-week old male Med19-AKO mice had modestly, but significantly increased body
weight (Figure 3.1E) despite similar food intake. Body composition analysis using EchoMRI
revealed reduced fat mass, but slightly increased lean mass in Med19-AKO mice (Figure 3.1E).
Weights of white fat depots (gWAT and iWAT) were dramatically reduced, but the BAT weight
was remarkably unchanged (Figures 3.1F). Liver weight was markedly increased in MED19AKO mice, explaining their elevated body weight. The small amount of remaining white fat in
Med19-AKO animals appeared unhealthy in histological sections showing sparse, irregular-sized
adipocytes among a fibrous extracellular matrix (Figure 3.1G). Gene expression analysis of the
iWAT and gWAT from Med19-AKO animals shows a decreased in adipocyte genes aP2,
C/EBPa, and PPARg (Figures 3.1I and 3.1J). However, C/EBPb and KLF5, which are both
activated early on in the adipogenic transcription cascade, appear to be elevated in Med19-AKO
animals suggesting that Med19 may play a role downstream of these factors in the adipogenic
transcription cascade. Med19 knockdown in iWAT SV cells in vitro blocked adipogenesis and
gene expression mirrored that of in vivo (Figure S3.2A and S3.2B). To determine if Med19
plays a specific role in adipose tissue development, we knocked down Med19 in C2C12 cells.
Med19 KD in C2C12 cells did not influence the ability of myoblasts to differentiate into
myotubes (Figure S3.2D and S3.2E), suggesting that Med19 plays a specific role in
adipogenesis in vitro. Given this initial data, we believe that Med19 is specific to WAT
adipogenesis rather than a general regulator of transcription. Previous work outside of our lab is
consistent with this notion showing that Med19 deficiency does not affect the structural integrity
of the Mediator in yeast or mammalian cells or cause a gross transcriptional defect and cell death
(Baidoobonso et al., 2007; Ding et al., 2009). Furthermore, assessment of cell viability using the
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WST-1 assay reagent confirmed that Med19 KD does not affect the metabolic health of both
differentiated iWAT SV cells and C2C12 myoblasts (Figures S3.2C and S3.2F).

3.3.3 Med19-AKO Mice Have Fatty Liver, Insulin Resistance, and Whitening
of Brown Fat.
Gross examination indicated that livers of 12-week old Med19-AKO animals were
enlarged and pale (Figure 3.2A), weighing approximately 75% more compared to WT
counterparts (Figure 3.2B), which possibly contributed to the increased body weight and lean
mass in these animals (Figure 3.1E and 3.1F). Histological examination showed significant
lipid droplet accumulation (Figure 3.2A) and measurement of liver triglyceride levels showed
that Med19-AKO mice had four-fold more liver triglyceride content (Figure 3.2C). Assessment
of glucose homeostasis revealed that Med19-AKO mice were hyperglycemic and glucose
intolerant (Figure 3.2D). In addition, Med19-AKO mice displayed an impaired response to
insulin in an insulin tolerance test (Figure 3.2E) as well as elevated fasting serum insulin levels
(Figure 3.2F). Knockout mice had impaired hepatic insulin signaling as assessed by
phosphorylation of Akt in response to insulin (Figure 3.2G and 3.2H). As previously noted,
Med19-AKO mice had no change in BAT mass (Figure 3.1F). However, at gross examination,
the intrascapular brown fat of knockout animals was much paler, resembling that of white
adipose tissue (Figure 3.2I). Given this observation, we wished to assess brown fat function.
Med19-AKO mice had decreased oxygen consumption as measured by indirect calorimetry
(Figure 3.2J) and were unable to defend their body temperature when exposed to cold (Figure
3.2K). Taken together, these results suggest a whitening of BAT and loss of thermogenic
function. However, this is likely due to the secondary “lipid spillover” effect cause by the
dramatic reduction of white adipose tissue in Med19-AKO animals.
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Figure 3.2 Med19-AKO mice have fatty liver, increased insulin resistance, and whitening of brown fat. A)
Gross and histological images of H&E stained liver sections. Scale bar = 75um. B) Liver weight of WT and Med19AKO mice. n = 9-10. C) Liver triglyceride content. n = 8-11. D-E) Glucose tolerance test (D, n = 13-20) and insulin
tolerance test (E, n = 7) in WT and Med19-AKO animals. F) Serum insulin ELISA. n = 4-5 G-H) Western blot of
insulin signaling in livers of Med19-AKO mice at baseline and 10 mins following insulin injection and quantified in
(H). n = 4. J) Indirect calorimetry. p < 0.001 by ANOVA. n = 4. K) Cold tolerance test of mice individually housed
at 4C. n = 4-5. *p < 0.05, **p < 0.005, ***p < 0.0005. The results are presented as mean ± SEM. All experiments
are done in 12-16-week-old mice.

3.3.4 Deletion of Med19 in Mature Adipose Causes Lipoatrophy Due to
Increased Apoptosis and Macrophage Infiltration
In order to investigate the role of Med19 is mature adipose tissue, we created an adiposespecific, tamoxifen-inducible Med19 knockout (Med19-iAKO) mouse line (Figure 3.3A and
3.3C). Med19-iAKO and lox/lox control mice were injected with 100mg/kg of tamoxifen for 5
consecutive days to induce adiponectin-cre expression (Figure 3.3B). Twenty-one days
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following tamoxifen injections, Med19-iAKO mice had no change in body weight (Figure
S3.3A) but did show a significant reduction in gWAT and iWAT mass (Figure 3.3D and
S3.2B). Similar to the Med19-AKO animals, there was no change in BAT mass (Figure 3.3D
and S3.1B). Med19-iAKO iWAT tissue displayed impaired lipolysis activity (Figure 3.3E) and
decreased lipolytic gene expression (Figure S3.3D) indicating that the decrease in fat mass was
not due to increased lipolysis. Western blot and immunohistochemistry staining of cleaved
caspase-3 revealed an accumulation of apoptotic cells in the iWAT of Med19-iAKO animals
(Figures 3.3F and 3.3G). Consistent with increased adipose tissue inflammation and death, we
observed significant macrophage infiltration in the gWAT and iWAT of Med19-AKO as
measured by F4/80 immunofluorescence staining (Figures 3.3H and 3.3I).
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Figure 3.3 Deletion of Med19 in mature adipose causes lipoatrophy due to increased apoptosis and
inflammation. A) Med19 floxed mice were crossed with Rosa26- CreER mice to generate adipose-specific,
tamoxifen-inducible Med19 KO (Med19-iAKO) mice. B) Schematic of experiment. 12-14-week-old Med19-iAKO
or control mice were injected with 100mg/kg of tamoxifen for 5 days. 21 days following injections tissue was
harvested. C) qPCR analysis of Med19 expression in adipose and liver of Med19-iAKO and control mice. n = 4-5
D) Tissue weight of Med19-iAKO mice normalized to body weight 21 days post tamoxifen injections n = 5. E)
Lipolysis assay in iWAT tissue explants from control and Med19-iAKO mice. n = 4
F) Immunohistochemical staining of iWAT tissue with cleaved caspase-3 antibody. G) Western blot of cleaved
caspace-3 in iWAT of control or Med19-iAKO mice. n = 4-5. H-I) Immunofluorescence images of
whole iWAT from control and Med19-iAKO mice 10 days post tamoxifen injections and quantified in (I). Blue =
DAPI, green = LipidTox, red = F4/80. *p < 0.05, **p < 0.005, ***p < 0.0005. The results are presented as mean ±
SEM. All experiments are done in 16-20-week-old mice.

3.3.5 Med19 Maintains Adipocyte Gene Expression By Facilitating PPARgMediated Gene Expression
In order to gain a better understanding of how Med19 regulates the transcriptional
landscape in adipose tissue, we performed RNA sequencing (RNA-seq) on gWAT of Med19iAKO mice 14 days post tamoxifen injection (Figures 3.4A) followed by KEGG pathway
analysis of genes that were significantly up-regulated or down-regulated in Med19-iAKO
animals compared to controls (Figures 3.4B and 3.4C). Induced genes established a clear
pattern of almost exclusively being involved in pathways associated with cell death,
inflammation, and inflammatory cell signaling/recruitment (Figure 3.4C). This analysis supports
the hypothesis that Med19 knockout in adipose tissue leads to lipoatrophy via cell death and
inflammation. KEGG pathway analysis for down-regulated genes identified pathways important
in both adipocyte-specific metabolism and signaling (Figure 3.4B). In particular, KEGG analysis
identified that genes involved in the PPAR signaling pathway were significantly downregulated
Med19-iAKO adipose tissue, suggesting that Med19 may be involved in facilitating PPARgmediated gene expression. In order to determine transcriptional circuits facilitated by Med19, we
applied the FDR-corrected data set of down-regulated genes identified in RNA-seq to
Hypergeometric Optimization of Motif EnRichment (HOMER) analysis (Heinz et al., 2010).
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This analysis found not only an enrichment of DNA-binding motifs for PPARg, but also the
adipogenic transcription factors C/EBPb and KLF4 (Figure 3.4D).
Given these findings and the similarities between our mice and those with adiposespecific deletion of PPARg (Wang et al., 2013), we wished to test if Med19 affects PPARgmediated gene expression, and created a tamoxifen-inducible Med19 KO, iWAT SV cell line
(Med19-iAKO) containing a PPARg luciferase reporter to do so. As shown in Figure 3.4E,
Med19 KO significantly blunted the ability of cells to activate the reporter in response to the
PPARg agonist rosiglitazone. To determine whether deletion of Med19 in adipocytes leads to
decreased occupancy of PPARg at PPARg response elements (PPREs) of target genes, we
performed chromatin immunoprecipitation (ChIP) assays in both control and Med19-iAKO
adipocytes. Consistent with our reporter assay in Figure 3.4E, ChIP-qPCR analysis of PPARg
binding to known PPREs (Lefterova et al., 2010; Rajakumari et al., 2013; Villanueva et al.,
2011) was significantly reduced in Med19-iAKO cells (Figure 3.4F). In line with ChIP data, we
found that knockout of Med19 in iWAT SV cells treated with adipogenic cocktail greatly
reduces the colocalization of PPARg with RNA PolII (as assessed by a proximity ligation assay)
to levels similar to those in unstimulated cells indicating that Med19 may be necessary for the
formation of an RNA PolII/PPARg adipogenic transcription complex (Figure 3.4G). Overall
these results suggest that Med19 is necessary for maintaining PPARg-mediated adipogenic gene
expression in white adipose tissue.

61

Figure 3.4 Loss of Med19 in mature adipose leads to decreased adipocyte and increased apoptotic gene
expression. A) Schematic of experiment. 12-week old Med19-iAKO mice were injected with 100mg/kg of
tamoxifen for 5 days. 14 days post tamoxifen gWAT was harvested for RNA-sequencing. B-C) Top 15 KEGG
pathways identified in FDR-corrected, downregulated (B) and upregulated (C) gene expression subsets. D) HOMER
known motif analysis based on a subset of FDR-corrected, downregulated genes. P-values represent enrichment of
indicated binding motif. E) Med19-iAKO iWAT SV cells were transfected with the reporter construct pLJM1PPRE-TK-Luc and pLJM1-FLAG-PPARg. Cells were differentiated before being treated with vehicle or 1uM 4hydroxy-tamoxifen (4OH TAM). Luciferase activity was then assessed before and after treatment with 1uM
rosiglitazone. n = 4 F) Med19-iAKO iWAT SV cells were differentiated and treated with vehicle or 4OH TAM
before being harvested. Chromatin immunoprecipitation was performed using an anti-PPARγ antibody, followed by
qPCR using primers for the indicated genes. Results are background corrected to a normal IgG control and
expressed as percent input. n = 3. G) Med19 KO blunts the colocalization of PPARγ with RNA PolII as measured by
proximity ligation assay in iWAT SV cells after stimulation with adipogenic cocktail. Red: PLA positive signal.
Blue: DAPI. *p < 0.05, **p < 0.005, ***p < 0.0005. The results are presented as mean ± SEM.

3.4 Discussion
Adipose is a complex tissue with profound influence over whole body metabolic health.
Adipose tissue development is an intricate process involving an array of transcription factors,
both known and unknown. Better understanding the underlying transcriptional regulation of
adipose tissue development and maintenance brings us closer to the possibility of utilizing
adipose tissue remodeling to decrease adiposity and improve insulin sensitivity in an effort to
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treat obesity and diabetes. As mentioned, an array of proteins has been implicated in the
development and maintenance of two functionally distinct types of adipose tissue, brown (BAT)
and white (WAT) fat, as well as the browning of white fat, but our understanding of these
processes remains incomplete.
The Mediator is a multi-subunit complex that acts as a bridge between gene-specific
transcription factors and the basal transcription machinery. Mediator subunit composition can
change with different subunits being added or lost to affect its biological function and ability to
interact with other transcription factors. However, very little is known about how this process is
regulated or about the specific function of the individual subunits (Allen and Taatjes, 2015).
Despite previous work being limited, studies have shown that Med19 is a non-essential Mediator
component in yeast and Med19 mutant yeast strains are viable with no impairment on gross
transcription (Dettmann et al., 2010). Also, deletion of Med19 does not disrupt the structural
integrity or function of the mediator complex in both yeast (Baidoobonso et al., 2007) and HeLa
cell extracts (Ding et al., 2009). Given these findings, Med19 is a subunit that likely functions in
specific pathways.
Here, we provide evidence that Med19 is essential in the development and maintenance
of WAT. In vitro knockdown of Med19 blocks the differentiation of iWAT SV cells but not
C2C12 myoblasts, indicating a cell type specific role of Med19 in adipocyte differentiation
(Supplementary Figure 3.2). Such a phenomenon is not unheard of as Med23 is also
dispensable for myoblast differentiation but is important for hormone-induced adipogenesis in
MEFs by facilitating the activity of Elk1 early on in the adipogenic transcription cascade (Wang
et al., 2009). As Med19 knockdown in iWAT SV cells prevented induction of downstream
adipogenic genes such as aP2 and C/EBPa, but had a little to no effect on the expression of
upstream genes such as C/EBPb and KLF5 (Supplementary Figure 3.2b), we reasoned to
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believe that perhaps Med19 was involved in the early stages of adipogenesis, similar to the role
of Med23. Unlike Med23, overexpression of C/EBPa, KLF5, PPARg, and overexpression of
PPARg in conjunction with the PPARg agonist rosiglitazone did not rescue the block in
adipogenesis seen with Med19 KD. This suggest that Med19 plays a direct role in facilitating
PPARg activity, as PPARg overexpression and agonism has been shown to not only be sufficient
for adipogenesis, but also to rescue upstream blocks in adipogenesis in vitro (Rosen et al., 2002;
Tontonoz et al., 1994; Wang et al., 2009; Zuo et al., 2006).
We were intrigued by these in vitro findings and moved on to an in vivo model. Adiposespecific deletion of Med19 (Med19-AKO) in mice resulted in near ablation of WAT leading to
hepatic insulin resistance and steatosis. BAT mass was unaffected, but Med19-AKO mice
manifested a significant whitening of the thermogenic fat. Typically when excess triglycerides
are dumped into the circulation, such as in the case of lipodystrophy, ectopic fat will accumulate
in peripheral tissues like the liver and skeletal muscle (Savage, 2009). We believe that the
dramatic whitening phenotype seen in our Med19-AKO mice is a secondary response to help
alleviate the lipid spillover caused by the disappearance of WAT. This result supports our in
vitro data suggesting Med19 has different functions in white versus brown adipose. Although
many genetic knockout mice have lipodystrophic phenotypes (Rochford, 2014; Savage, 2009), it
is rare to see such a severe defects in WAT development that is not also seen in the BAT. Mice
with a heterozygous KO for KLF5 (KLF+/-) show significant defects in neonatal WAT
development, but intrascapular BAT mass showed no difference to WT littermates (Oishi et al.,
2005). Similarly, C/EBPa null mice rescued by transgenic hepatic expression have an absence of
WAT with no defects in BAT outside of mild adipocyte hypertrophy (Linhart et al., 2001).
To study the effect of Med19 KO in mature adipose tissue, we created an adiposespecific, tamoxifen-inducible Med19 knockout (Med19-iAKO) mouse line, which possessed a
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similar phenotype to Med19-AKO animals, including a significant reduction in WAT, but not
BAT, mass. As mentioned previously, when we knocked down Med19 in iWAT SV cells, the
cells failed to differentiate and form lipid droplets (Supplementary Figure 3.2A-B).
Interestingly, when we knocked out Med19 in fully differentiated adipocytes, we observed no
change in lipid droplet accumulation, expression of adipocyte genes, or cell death suggesting the
role of Med19 in maintenance of mature adipocytes is more nuanced than the developmental
defect. Overall, the RNA-seq analysis of Med19-iAKO gWAT painted a picture of an unhealthy
tissue struggling to maintain adipose-specific gene expression, resulting in loss of adipose tissue,
likely due to the upregulation of genes involved in apoptosis, necroptosis, and inflammation. Of
note, one of the top downregulated KEGG pathways identified in Med19-iAKO gWAT was
PPARg signaling (Figure 3.4B). The WAT in Med19-iAKO animals showed a marked increase
in macrophage infiltration and accumulation of apoptotic cells (Figure 3.3F-I), a phenotype very
similar to that of mice with adipose-specific deletion of PPARg (Wang et al., 2013). These data,
along with the observation that PPARg overexpression and agonism was unable to rescue the
Med19 KD phenotype in vitro suggest that perhaps Med19 is necessary for mediating PPARg
activity. Indeed, HOMER analysis of our RNA-seq dataset revealed that expression of genes
containing PPARg binding motifs were highly downregulated in Med19-iAKO gWAT (Figure
3.4D), further implicating Med19 in PPARg signaling. Med19-iAKO iWAT SV cells showed
reduced residency of PPARg on adipose-specific target genes and were also unable to activate a
PPARg luciferase reporter when treated with the PPARg agonist rosiglitazone (Figure 3.4E-F).
Med19 is a component of the Mediator protein complex, the function of which is to facilitate the
interaction between RNA PolII and gene specific transcription factors, such as PPARg, in order
to drive gene expression. We used a proximity ligation (PLA) assay to demonstrate that the
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ability of PPARg to associate with RNA PolII is markedly reduced in the absence of Med19
(Figure 3.4G). Although Med19 does not directly interact with PPARg, it is likely that Med19
coordinates the association of other unidentified transcription factors in order to facilitate the
PPARg/RNA PolII interaction. Taken together, these results identify Med19 as a crucial
facilitator of PPARg-mediated gene expression that is selectively required for the development
and maintenance of WAT.
The identification and designation of transcription factors as “master regulators” of their
specific biological process or transcriptional program, such as PPARg in the case of adipose
tissue, has become a trend in the current research with the number of articles containing the term
growing exponentially (Kin Chan, 2013). Besides PPARg, other examples include MyoD in the
case of skeletal muscle, Runx2 in osteocytes, and Nanog in pluripotent stem cells (Boyer et al.,
2005; Davis et al., 1987; Schroeder et al., 2005). Emerging research has provided evidence of
several Mediator components interacting with transcription factors considered to be master
regulators of their distinct biological processes. Med23 interacts with Runx2 to regulate
osteoblast differentiation, Med12 works hand-in-hand with Nanog to regulate embryonic stem
cell development, and Med12 and Med25 cooperate with Sox9 in chondrocyte differentiation
(Liu et al., 2016; Nakamura et al., 2011; Tutter et al., 2009; Zhou et al., 2002). PPARg also has a
history of working with Mediator to facilitate its activity. MEFs from Med1 KO embryos have
defects in PPARg-target gene expression and PPARg-mediated adipogenesis (Ge et al., 2002).
However, adipogenesis is not impaired in MEFs expressing a Med1 mutant lacking LxxLL
motifs that is unable to interact with PPARg, suggesting an alternative mechanism by which the
Mediator is recruited to PPARg target genes independent of Med1 (Ge et al., 2008b). Later work
concluded that Mediator is recruited to PPARg via Med14 which directly interacts with the N66

terminus of PPARg (Grontved et al., 2010). It is clear that the Mediator complex plays a key role
in facilitating PPARg-mediated gene expression. Here, we contribute to this understanding by
establishing Med19 as a specific and essential component to the PPARg/Mediator complex in
adipogenesis.

3.5 Materials and Methods
3.5.1 Cell Lines
Human embryonic kidney 293T (HEK293T) cells were maintained in DMEM
supplemented with 10% FBS. Stromal vascular fractions from mouse iWAT and BAT were
isolated, immortalized, and differentiated into adipocytes as previously reported (Lodhi et al.,
2017; Park et al., 2019b). For brown adipogenesis, BAT SV cells were treated with DMEM/F12
supplemented with 0.5 μM isobutylmethylxanthine, 5 μM dexamethasone, 125 μM
indomethacin, 1 μM rosiglitazone, 1 nM T3, and 0.02 μM insulin. After 2 days, the cells were
switched to medium supplemented with only 1 nM T3 and 0.02 μM insulin (maintenance
medium), which was replaced every 2 days. For white adipogenesis, iWAT SV cells were
differentiated into adipocytes by treating confluent cells with DMEM/F12 supplemented with
5ug/ml

insulin,

0.25uM

Dexamethasone,

1µM

rosiglitazone,

and

0.5

µM

isobutylmethylxanthine. After two days, the cells were switched to medium supplemented with
only 1 µM rosiglitazone and 5ug/ml insulin. Inducible Med19 KO iWAT SV cells (Med19-iKO)
were created by treating iWAT SV cells obtained from Med19flox/flox animals and infecting them
with MSCV CreERT2 puro retrovirus (Addgene #22776) (Kumar et al., 2009). C2C12 cells were
maintained in DMEM supplemented with 10% FBS. To induce differentiation, C2C12 cells at
~80% confluence were switched to DMEM containing 2% horse serum. For lentiviral
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experiments, 293T cells in 10 cm dishes were transfected with 2.66 µg psPAX2, 0.75 µg
pMD2.G (both packaging constructs), and 3 µg expression plasmid. After 48h., conditioned
media was collected, filtered using 0.45 µm syringe filters, and used to infect cells. After 36h.,
cells were selected using the appropriate drug. Cell viability was assessed by colorimetric assay
using Cell Proliferation Reagent WST-1 (Roche).

3.5.2 Plasmid Constructs
Plasmids encoding lentivirus shRNA for mouse Med19 (TRCN000258189) was obtained
from Sigma-Aldrich (St. Louis, MO). Packaging vector psPAX2 (12260), envelope vector
pMD2.G (12259), and scrambled shRNA plasmid (1864) were obtained from Addgene. FLAGMed19 lentiviral overexpression plasmid was generated by replacing eGFP with FLAG-Med19
(GenScript OMu01220) in pLJM1-eGFP (Addgene #19319) (Sancak et al., 2008). Luciferase
PPRE-TK luc plasmid. PPRE-TK-Luc lentiviral reporter plasmid was generated by replacing the
CMV-eGFP insert in pLJM1-eGFP with PPRE-TK-luciferase from the PPRE X3-TK-luc
plasmid (Addgene #1015) (Kim et al., 1998). Similarly, the pLJM1-Flag-PPARg was created by
cloning flag tagged PPARγ in place of eGFP in the pLJM1-eGFP vector.

3.5.3 Mouse Lines
To create Med19-AKO mice, we obtained mice with conditional-potential allele of
Med19 (Med19tm1a(EUCOMM)Wtsi) from the EUCOMM repository and crossed them with actin-Flp
transgenic mice to remove the targeting cassette and then subsequently crossed the mice with
adiponectin-Cre mice to generate adipose-specific Med19 knockout (Med19-AKO) mice. To
generate adipose-specific, tamoxifen-inducible Med19 KO (Med19-iAKO) mice, Med19 floxed
animals were crossed with Rosa26- CreER mice obtained from The Jackson Laboratory. To
induce knockout, 12-week-od control (Med19lox/lox without Cre) and Med19-iAKO mice were
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treated daily with tamoxifen (100 µg/g body weight) for five consecutive days. All protocols
were approved by the Washington University Animal Studies Committee.

3.5.4 Immunohistochemistry and Immunofluorescence Imaging
For C2C12 cell IF imaging, cells were fixed using ice-cold methanol at -20C for 10 mins
and permeabilized with 0.1% Triton X-100 in PBS (PBS-T). Cells were incubated with primary
MYH1 anti-mouse (DSHB MF20) antibody at 1:100 dilution in PBS-T at 4C overnight. Alexafluor conjugated secondary antibody (Invitrogen A-11008) was used at a dilution of 1:500 at
room temperature for 1 hr. For IHC detection of cleaved caspase-3, formalin-fixed, paraffinembedded adipose tissue sections were de-paraffinized and incubated with anti-cleaved caspase3 antibody (Cell Signaling Technology D175) followed by detection using the Vectastain
Universal Elite ABC kit (Vector Labs) before being mounted and imaged with a Leica
DMI4000B fluorescence microscope. Immunofluorescent imaging of whole adipose tissue was
done as previously described (Berry et al., 2014). Briefly, freshly harvested adipose tissue was
washed with PBS before being incubated with Alexa fluor 647-conjugated Rat anti-mouse F4/80
antibody (Biolegend 123121) at 1:100 overnight, HCS LipidTox (Invitrogen H34475) at 1:100
for 1hr, and DAPI (Invitrogen D1306) at 1:10,000 for 1hr. After antibody incubation tissue was
washed and mounted using Vectashield mounting medium (Vector Laboratories H-1000) and
imaged Nikon A1Rsi Confocal Microscope. Quantification was performed using ImageJ
software.

3.5.5 PPRE Luciferase Assay
Med19-iKO iWAT SV cells were transduced with both pLJM1-FLAG-PPARg and
pLJM1-PPRE-TK-Luciferase reporter lentivirus, and antibiotic selected to create stable cell
lines. Cells were differentiated 3 days before being adding media containing vehicle or 469

hydroxytamoxifen for 3 days with or without 1µM rosiglitazone. Cells were harvested and
luminescence was measured using a Luciferase Assay System kit (Promega E1500).
Luminescence was normalized to cellular protein as measured by Pierce BCA Assay kit (Thermo
Fisher 23227).

3.5.6 RT-qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen 15596026) or PureLink RNA
Mini Kit (Invitrogen 12183018A) and reverse transcribed using High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems 4368814). qPCR was performed with a StepOnePlus
Real-Time PCR System (Applied Biosystems) using PowerUP SYBR Green Master Mix
(Applied Biosystems A25742). Assays were performed in duplicate and normalized to ribosomal
protein L32.

3.5.7 Antibodies
The Anti-FLAG (F1804) and anti-RNA PolII (05-623) antibodies was obtained from
Millipore Sigma. Antibodies against HA (sc-805) and Actin (sc-1616) were obtained from Santa
Cruz. Antibodies against pAKT (9271), AKT (9272), PPARg (81B8) and cleaved caspase-3
(9661) were obtained from Cell Signaling Technologies. Anti-MYH1 antibody (MF20) was
obtained from the Developmental Studies Hybridoma Bank. The Alexa fluor 647 conjugated
anti-F4/80 antibody (123121) was obtained from BioLegend.

3.5.8 Insulin ELISA and Insulin Signaling Assay
Serum was collected from 16-week old Med19-AKO males and insulin concentration
was measured using an Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem 90080)
according to manufacturer’s suggested protocol. To measure insulin signaling in the liver, mice
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were fasted for 4-6h before tissue was collected and quickly frozen at the basal state or 10 mins
after an IP injection of 5mU/g of insulin (Humulin R, Lilly).

3.5.9 Indirect Calorimetry
To measure basal VO2, carbon dioxide production (VCO2), respiratory exchange ratio
(RER), and physical activity in Med19-AKO mice, a PhenoMaster (TSE Systems) metabolic
cage system was used. Mice were acclimated to the system for 24 hours before measurements
were taken.

3.5.10 Ex Vivo Lipolysis Assay
Ex vivo lipolysis assay was performed using the Lipolysis Colorimetric Assay Kit
(Sigma, MAK211) according to manufacturer’s instructions. Briefly, iWAT from WT and
Med19-iAKO mice was harvested, minced, and ~50mg of tissue was cultured in 24-well plates
overnight in DMEM F-12 containing insulin and dexamethasone. Tissue was washed 2x with
adipocyte wash buffer and incubated in lipolysis buffer with or without 100nM isoproterenol for
1.5h before measuring the amount of glycerol in the media.

3.5.11 RNA-sequencing and Analysis
gWAT was collected from 12 to 13-week-old female control or Med19-iAKO mice 14
days post tamoxifen injections. RNA was harvested using a combination of TRIzol reagent
(Invitrogen 15596026) and PureLink RNA Mini Kit (Invitrogen 12183018A) before being
submitted to the Genome Technology Access Center (GTAC) at Washington University School
of Medicine in St. Louis for sequencing and analysis. We thank the Genome Technology Access
Center in the Department of Genetics at Washington University School of Medicine for
help with genomic analysis. The Center is partially supported by NCI Cancer Center Support
Grant #P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant# UL1TR002345
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from the National Center for Research Resources (NCRR), a component of the National
Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely
the responsibility of the authors and does not necessarily represent the official view of NCRR or
NIH.

3.5.12 Chromatin Immunoprecipitation
ChIP studies were conducted using the SimpleChIP Enzymatic Chromatin IP Kit (Cell
Signaling Technology) according to manufacturer’s instruction and as previously described
(Lodhi et al., 2017). Briefly, Med19-iKO iWAT SV cells were stimulated with differentiation
media for 2 days before being switched to maintenance media with or without 4-hydroxytamoxifen for 2 days before being harvested. Cells were fixed with 1% formaldehyde for 15
mins. Nuclei were harvested and chromatin digested by micrococcal nuclease before being lysed
on ice by 3 sets of 10-second pulses from a Sonics VCX 500 probe sonicator at 30% amplitude.
Chromatin was clarified by centrifugation before being incubated with normal rabbit IgG or
rabbit anti-PPARg (Cell Signaling Technology 81B8) antibodies at 4C overnight. ChIP-Grade
protein G agarose beads were incubated for 4 hours, spun, and washed. Crosslinks were reversed
and DNA was purified by spin column. DNA was quantified by qPCR using PowerUp Sybr
Green Master Mix (Thermo Fisher) in triplicate and data are shown as percentage of input.
Primer sequences used in qPCR are as described previously (Aguilar et al., 2010; Lefterova et
al., 2010; Park et al., 2016; Rajakumari et al., 2013; Villanueva et al., 2011)

3.5.13 Proximity Ligation Assay
Proximity ligation assays were performed using Duolink reagents (Sigma) according to
the manufacturer’s instructions with PPARg (Cell Signaling 81B8) and RNA PolII (SigmaAldrich 05-623) primary antibodies. Med19-iKO iWAT SV cells were differentiated into
72

adipocytes by treating confluent cells with DMEM/F12 supplemented with 5ug/ml insulin, 0.25
µM Dexamethasone, 1µM rosiglitazone, and 0.5uM isobutylmethylxanthine. After two days, the
cells were switched to medium supplemented with only 1µM rosiglitazone and 5ug/ml insulin
with or without 1µM 4OHT for two days before being used in experiments.

3.5.14 Pulldown Assays
GST-pull-down and immunoprecipitation assays were performed as previously described
(Lodhi et al., 2012, 2017). Briefly, cells were lysed using a buffer containing 50 mM HEPES
(pH 7.4), 4 mM EDTA, 2 mM EGTA, 2 mM sodium pyrophosphate, 1% Triton X-100, 10 mM
NaF, and protease inhibitors (P8340; Sigma-Aldrich). Cell lysates were mixed with an equal
volume of the same buffer containing no Triton X-100, then 5 mg of GST alone beads or GST
fusion protein beads and rocked at 4C for 2 hr. Samples were spun down at 2,500g for 1 min and
washed five times with lysis buffer containing 0.5% Triton X-100 before being resuspended in
SDS sample buffer and subjected to SDS-PAGE.

3.5.15 Statistical Analysis
Data are expressed as mean ± SEM. Comparisons between two groups were performed
using an unpaired, two-tailed t test. Statistical analysis and graphs were generated using
GraphPad Prism software.
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3.6 Supplemental Figures

Supplemental Figure 3.1 Med19 interacts with PexRAP. A) GST-PexRAP interacts with FLAG-Med19. B) HAPexRAP co-immunoprecipitates with FLAG-Med19 in 293T cells.
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Supplementary Figure 3.2 Med19 is specifically necessary for white adipogenesis in vitro. A) Oil Red O
staining of neutral lipids in differentiated iWAT SV cells treated with scrambled or Med19 shRNA.
B) qPCR analysis of differentiated iWAT SV cells. n = 3. C) Med19 KO has no effect on metabolic activity of
adipocytes as measured by WST assy. n = 3. D) Immunofluorescence images of differentiated C2C12 cells stained
with DAPI in blue and myosin heavy chain (MHC) antibody in green at 50x magnification. E) qPCR analysis of
differentiated C2C12 cells treated with scrambled or Med19 shRNA. F) Med19 KO has no effect on metabolic
activity of myocytes as measured by WST assy. n= 3. *p < 0.05, **p < 0.005, ***p < 0.0005. The results are
presented as mean ± SEM.
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Supplementary Figure 3.3 Med19-iAKO Mice. A) Body weight of Med19-iAKO mice 21 days following TAM
injections. n =5. B) Gross images of iWAT, gWAT, and BAT from Med19-iAKO mice 21 days post TAM
injections. C) Histology images of iWAT, gWAT, and BAT from Med19-iAKO mice 21 days following TAM
injections. D) Expression of lipolysis genes are reduced in iWAT of Med19-iAKO mice. *p < 0.05, **p < 0.005,
***p < 0.0005. The results are presented as mean ± SEM.
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Chapter 4: Future Directions
4.1 Delineating the Nuclear Localization and Lipid Synthetic
Function of PexRAP in Adipocyte Differentiation
Previously, we identified a lipogenic pathway encompassing fatty acid synthase (FAS)
and a peroxisomal protein called PexRAP (Peroxisomal Reductase Activating PPARg) that
synthesizes ether lipids, potential partial agonists of PPARγ (Lodhi et al., 2012). Further work
highlighted in this dissertation revealed that PexRAP is also localized in the nucleus where it
interacts with PPARγ and PRDM16 and disrupts PRDM16-mediated thermogenic gene
expression (Lodhi et al., 2017), demonstrating that PexRAP possesses transcription co-regulator
activity that extends beyond its established role as a peroxisomal lipid synthetic enzyme involved
in the creation of endogenous PPARg ligands. Together these results emphasize the multifaceted
nature of PexRAP: the ability to influence adipogenesis both through peroxisomal lipid synthetic
and nuclear transcriptional regulatory activities. However, we have not been able to clearly
separate the functions of these activities and their role in adipocyte differentiation.
In order to delineate PexRAP enzymatic function from its nuclear function, we have
created various expression constructs of PexRAP functional mutants. We suggest isolating
iWAT SV cells from PexRAP-iKO mice and then ectopically expressing these constructs
containing wild-type, DNLS, DLxxLL, or PexRAPG65D before treating the cells with vehicle of 4hydroxy-tamoxifen to knockout endogenous PexRAP. The PexRAP expression constructs
(Figure 4.1.1) were created by cloning FLAG-tagged PexRAP mutants in the place of AmCyan
in the AmCyan-P2A-mCherry construct (Addgene #45350) whose CMV promoter has been
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replaced with the endogenous PexRAP promoter region (-2500 to 0). Use of the endogenous
promoter will ensure that the mutants will be expressed at physiologically relevant levels similar
to endogenous PexRAP. The DNLS and DLxxLL mutants we have previously described (Lodhi
et al., 2017) as preventing PexRAP from interacting with importin-b or PPARγ, respectively.
The G65D mutant is a catalytically dead form of PexRAP. As discussed previously in detail in
Chapter 1.3 and outlined in Figure 1.2, ether lipids are synthesized by the acyl dihydroxyacetone
phosphate (DHAP) pathway in peroxisomes (Cipolla and Lodhi, 2017; Dean and Lodhi, 2017).
Previously, we identified PexRAP (gene name Dhrs7b) as the acyl/alkyl DHAP reductase
(ADHAPR) enzyme that catalyzes the terminal peroxisomal step in this pathway (Lodhi et al.,

2012). Recently, our lab sequenced PexRAP in mutant CHO-K1 cells published to have virtually
complete loss of ADHAPR enzyme activity (James et al., 1997) and identified a G65D mutation
in the reductase domain, thus suggesting that this mutation of PexRAP results in a catalytically
dead enzyme. We suggest these PexRAP iAKO iWAT SV cells expressing WT and mutant
forms of PexRAP be differentiated into adipocytes and protein expression and localization
analyzed by immunofluorescent confocal microscopy and subcellular fraction followed by
western blot. Adipogenesis should be assessed by Oil Red O assay and by measuring the
expression of adipogenic markers via qPCR and western blot both before and after
differentiation in all cell lines. Cellular lipids should be extracted using the Bligh and Dyer
method and analyzed by mass spec to assess PexRAP enzymatic activity.
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Figure 4.1.1 Schematic of PexRAP mutant constructs.

We expect that PexRAP-DNLS will fail to translocate to the nucleus resulting in
decreased nuclear function. We predict this will result in impaired nuclear lipid synthesis which,
in turn, could affect gene expression since PexRAP synthesized either-linked phospholipids may
be involved in PPARg activation (Lodhi et al., 2012). Therefore, we would expect the PexRAPDNLS cell line to show impaired adipogenesis similar to that of PexRAP KD. It is also possible
that an altered gene expression profile in the DNLS mutant could be unrelated to impaired lipid
synthesis since PexRAP can directly interact with nuclear receptors. The use of the G65D and
DLxxLL mutants should clarify this ambiguity. It is possible that the mutant cell lines could have
impaired adipogenesis. This would confound interpretation of direct effects on gene expression
and/or lipid synthesis.

4.2 Determining the Role of Med19 in Brown Adipose Tissue
Development and Maintenance
It is clear that Med19 is essential for white adipose tissue development and maintenance.
However, in both Med19-AKO and Med19-iAKO mice despite a near loss of WAT mass, BAT
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mass remains unchanged (Figures 3.1F and 3.3D). This suggests perhaps Med19 is dispensable
in BAT. To test this hypothesis, we treated BAT SV cells with Med19 shRNA and then
attempted to differentiate them using a BAT-specific adipogenic cocktail). Not only did Med19
knockdown have no effect on adipogenesis as measured by oil red O staining and adipogenic
gene expression (Figure 4.2.1A), but Med19 KD even appeared to enhance the expression of
thermogenic genes such as UCP1 and PRDM16. This is in direct contrast to the result seen with
iWAT SV cells in Supplementary Figure 3.2A-B. Even though the mass BAT in Med19-AKO
was unaffected, the tissue showed a significant whitening effect as seen in gross appearance and
increase of lipid droplet size in histology (Figure 3.2I). As previously mentioned, this is
believed to be a secondary lipid spillover effect due to the massive reduction of WAT mass in
Med19-AKO mice. In line with this hypothesis, acute KO in Med19-iAKO mice did not lead to
the same dramatic whitening of BAT likely due to the lipid spillover effect not having as much
time to take place. Regardless, we next wished to study the effects of the loss of Med19 in BAT
in vivo without the confounding secondary effects in WAT created by the use of adiponectin cre.
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Figure 4.2.1 Med19 knockdown in BAT SV cells has no effect on adipogenesis and enhances thermogenic gene
expression. A) Oil red O staining showing no change in lipid accumulation between scrambled and Med19 shRNA
treated BAT SV cells after differentiation with a brown adipogenic cocktail. B) Gene expression analysis of
differentiated BAT SV cells treated with scrambled or Med19 shRNA n = 3. *p < 0.05, **p < 0.005, ***p < 0.0005.
The results are presented as mean ± SEM.

To achieve this, we created a brown fat-specific Med19 knockout (Med19-BKO) mouse
line by crossing Med19 floxed animals with those expressing cre recombinase under control of
the UCP1 promoter (Figure 4.2.2A) and performed some preliminary analyses on a small cohort.
These mice displayed no changes in gross appearance of liver, gWAT, iWAT, or BAT and had
similar body weights (Figure 4.2.2B and 4.2.2C). Upon closer examination, both liver and BAT
of Med19-BKO mice had slightly less mass than WT counterparts (Figure 4.2.2C). When
studying Med19-iAKO mice, we performed histological analysis and noticed that the KO
animals had significantly smaller lipid droplets in their BAT compared to WT counterparts
(Supplementary Figure 3.3C). Although we have yet to do histological analysis on the BAT of
Med19-BKO animals, it is possible that they do have smaller lipid droplets which could explain
their decrease in mass. At this point, the cause of this phenomenon is unknown. Further
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experiments will be needed to determine if loss of Med19 in BAT causes decreased lipid
accumulation due to increased lipolysis, increased thermogenesis, or some other mechanism.
Gene expression analysis of BAT in Med19-BKO mice showed decreased expression of most
adipose and thermogenic genes (Figure 4.2.2D). This result is unexpected given our in vitro
findings that Med19 knockdown leads to no change in adipogenic genes and an increase in the
thermogenic genes UCP1 and PRDM16 (Figure 3.2.1B). Paradoxically, Med19-BKO animals
had no problem defending their body temperature when individually housed at 4C (Figure
4.2.2E), despite having impaired thermogenic gene expression (Figure 4.2.2D).

Figure 4.2.2 Creation of brown adipose-specific Med19 knockout (Med19-BKO) mice. A) Med19 floxed
animals were crossed with animals expressing cre under control of the UCP1 promoter to create Med19-BKO mice.
B) Gross images of liver, gWAT, iWAT, and BAT taken from lox/lox and Med19-BKO mice. C) Body weight and
tissue weight (expressed as percentage of body weight) of lox/lox and Med19-BKO mice. Both liver and BAT
weight are modestly decreased in Med19-BKO animals n = 3-4. D) Gene expression analysis of BAT from lox/lox
and Med19-BKO animals n = 3-4. E) Cold tolerance test of mice individually housed at 4C. n = 3-4. *p < 0.05. The
results are presented as mean ± SEM. All experiments are done in 14-18-week-old female mice.

Our preliminary studies on this initial cohort of Med19-BKO mice have provided us with
more questions than answers. Med19 clearly functions differently in brown than in white adipose
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tissue, yet its specific function is still unclear. To help understand the unique role of med19 in
BAT, we suggest performing a complete characterization on a larger cohort of Med19-BKO
animals as we have done previously with our Med19-AKO animals. To further asses
thermogenesis we suggest performing a cold tolerance test on a larger cohort of Med19-BKO
mice. In addition, we suggest more specifically determining BAT thermogenic capacity, by using
subdermal temperature probes to locally measure the heat production of BAT in response to
norepinephrine injections or cold stimulus as well as measuring oxygen consumption of BAT
explants. BAT mass appears to be slightly decreased in Med19-BKO animals (Figure 4.2.2C),
which may be due to decreased lipid droplet size as alluded to in our Med19-iAKO animals
(Supplementary Figure 3.3C). To measure this, we suggest performing histology and staining
for neutral lipids as well as directly measuring triglycerides in BAT of Med19-BKO mice. In
order to understand role of Med19 in regulating brown adipocyte gene expression, RNA-seq
should be utilized to identify transcriptional targets of Med19 and open up new avenues of
research.
Ultimately, to best understand the different mechanisms by which Med19 regulates both
white and brown adipose tissue gene expression, we must identify Med19-interacting partners in
these tissues. To do this, we propose utilizing a mass-spec-based approach to identify Med19interacting proteins during adipogenesis as follows: iWAT/BAT SV cells infected with lentivirus
expressing

FLAG-Med19

will

be

differentiated,

lysed,

and

lysate

subjected

to

immunoprecipitation using either an IgG control or anti-FLAG antibody. Following analysis of
the data, proteins that are significantly enriched in the FLAG over IgG pulldown will be
considered Med19 interactors and confirmed through immunoprecipitation and pursued in future
experiments to generate new hypotheses. We are hopeful this will shed more light onto the
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mechanisms by which Med19 helps coordinate different transcription complexes in both white
and brown adipose tissue.

84

References
Aguilar, V., Annicotte, J.-S., Escote, X., Vendrell, J., Langin, D., and Fajas, L. (2010). Cyclin
G2 regulates adipogenesis through PPARγ coactivation. Endocrinology 151, 5247–5254.
Ahmadian, M., Suh, J.M., Hah, N., Liddle, C., Atkins, A.R., Downes, M., and Evans, R.M.
(2013). PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 99, 557–
566.
Albert, D.H., and Anderson, C.E. (1977). Ether-linked glycerolipids in human brain tumors.
Lipids 12, 188–192.
Albert, C.J., Thukkan, A.K., Heuertz, R.M., Slungaard, A., Hazen, S.L., and Ford, D.A. (2003).
Eosinophil Peroxidase-derived Reactive Brominating Species Target the Vinyl Ether Bond of
Plasmalogens Generating a Novel Chemoattractant, alpha -Bromo Fatty Aldehyde. J. Biol.
Chem. 278, 8942–8950.
Allen, B.L., and Taatjes, D.J. (2015). The Mediator complex: a central integrator of transcription.
Nat. Rev. Mol. Cell Biol. 16, 155–166.
Alshehry, Z.H., Mundra, P.A., Barlow, C.K., Mellett, N.A., Wong, G., McConville, M.J., Simes,
J., Tonkin, A.M., Sullivan, D.R., Barnes, E.H., et al. (2016). Plasma Lipidomic Profiles Improve
on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes
MellitusClinical Perspective. Circulation 134, 1637–1650.
Association, A.D. (2013). Economic costs of diabetes in the US in 2012. Diabetes Care 36,
1033–1046.
Baidoobonso, S.M., Guidi, B.W., and Myers, L.C. (2007). Med19(Rox3) Regulates Intermodule
Interactions in the Saccharomyces cerevisiae Mediator Complex. J. Biol. Chem. 282, 5551–
5559.
Barøy, T., Koster, J., Strømme, P., Ebberink, M.S., Misceo, D., Ferdinandusse, S., Holmgren, A.,
Hughes, T., Merckoll, E., Westvik, J., et al. (2015). A novel type of rhizomelic chondrodysplasia
punctata, RCDP5, is caused by loss of the PEX5 long isoform. Hum. Mol. Genet. 24, 5845–
5854.
Barr, J., Caballería, J., Martínez-Arranz, I., Domínguez-Díez, A., Alonso, C., Muntané, J., PérezCormenzana, M., García-Monzón, C., Mayo, R., Martín-Duce, A., et al. (2012). ObesityDependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression.
J. Proteome Res. 11, 2521–2532.
85

Benjamin, D.I., Cozzo, A., Ji, X., Roberts, L.S., Louie, S.M., Mulvihill, M.M., Luo, K., and
Nomura, D.K. (2013). Ether lipid generating enzyme AGPS alters the balance of structural and
signaling lipids to fuel cancer pathogenicity. Proc. Natl. Acad. Sci. 110, 14912–14917.
Berry, R., Church, C.D., Gericke, M.T., Jeffery, E., Colman, L., and Rodeheffer, M.S. (2014).
Imaging of Adipose Tissue. In Methods in Enzymology, (Elsevier), pp. 47–73.
Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G.,
Kumar, R.M., Murray, H.L., Jenner, R.G., et al. (2005). Core Transcriptional Regulatory
Circuitry in Human Embryonic Stem Cells. Cell 122, 947–956.
Bräutigam, C., Engelmann, B., Reiss, D., Reinhardt, U., Thiery, J., Richter, W.O., and Brosche,
T. (1996). Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and
patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis 119, 77–88.
Braverman, N.E., and Moser, A.B. (2012). Functions of plasmalogen lipids in health and disease.
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1822, 1442–1452.
Braverman, N., Steel, G., Obie, C., Moser, A., Moser, H., Gould, S.J., and Valle, D. (1997).
Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic
chondrodysplasia punctata. Nat. Genet. 15, 369–376.
Brites, P. (2003). Impaired neuronal migration and endochondral ossification in Pex7 knockout
mice: a model for rhizomelic chondrodysplasia punctata. Hum. Mol. Genet. 12, 2255–2267.
Brites, P., Ferreira, A.S., Ferreira da Silva, T., Sousa, V.F., Malheiro, A.R., Duran, M.,
Waterham, H.R., Baes, M., and Wanders, R.J.A. (2011). Alkyl-Glycerol Rescues Plasmalogen
Levels and Pathology of Ether-Phospholipid Deficient Mice. PLoS ONE 6, e28539.
Brodde, A., Teigler, A., Brugger, B., Lehmann, W.D., Wieland, F., Berger, J., and Just, W.W.
(2012). Impaired neurotransmission in ether lipid-deficient nerve terminals. Hum. Mol. Genet.
21, 2713–2724.
Broniec, A., Klosinski, R., Pawlak, A., Wrona-Krol, M., Thompson, D., and Sarna, T. (2011).
Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model
systems. Free Radic. Biol. Med. 50, 892–898.
Broniec, A., Żądło, A., Pawlak, A., Fuchs, B., Kłosiński, R., Thompson, D., and Sarna, T.
(2017). Interaction of plasmenylcholine with free radicals in selected model systems. Free Radic.
Biol. Med. 106, 368–378.
Buchert, R., Tawamie, H., Smith, C., Uebe, S., Innes, A.M., Al Hallak, B., Ekici, A.B., Sticht,
H., Schwarze, B., Lamont, R.E., et al. (2014). A Peroxisomal Disorder of Severe Intellectual
Disability, Epilepsy, and Cataracts Due to Fatty Acyl-CoA Reductase 1 Deficiency. Am. J. Hum.
Genet. 95, 602–610.
86

Cader, M.Z., Boroviak, K., Zhang, Q., Assadi, G., Kempster, S.L., Sewell, G.W., Saveljeva, S.,
Ashcroft, J.W., Clare, S., Mukhopadhyay, S., et al. (2016). C13orf31 (FAMIN) is a central
regulator of immunometabolic function. Nat. Immunol. 17, 1046–1056.
Chen, W., Yang, Q., and Roeder, R.G. (2009). Dynamic Interactions and Cooperative Functions
of PGC-1α and MED1 in TRα-Mediated Activation of the Brown-Fat-Specific UCP-1 Gene.
Mol. Cell 35, 755–768.
Chen, X., Chen, H., Dai, M., Ai, J., Li, Y., Mahon, B., Dai, S., and Deng, Y. (2016). Plasma
lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from
benign lesions. Oncotarget 7, 36622–36631.
Cipolla, C.M., and Lodhi, I.J. (2017). Peroxisomal Dysfunction in Age-Related Diseases. Trends
Endocrinol. Metab.
Cohen, P., Levy, J.D., Zhang, Y., Frontini, A., Kolodin, D.P., Svensson, K.J., Lo, J.C., Zeng, X.,
Ye, L., Khandekar, M.J., et al. (2014). Ablation of PRDM16 and Beige Adipose Causes
Metabolic Dysfunction and a Subcutaneous to Visceral Fat Switch. Cell 156, 304–316.
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B., Kuo, F.C., Palmer,
E.L., Tseng, Y.-H., Doria, A., et al. (2009). Identification and Importance of Brown Adipose
Tissue in Adult Humans. N. Engl. J. Med. 360, 1509–1517.
Davies, S.S., Pontsler, A.V., Marathe, G.K., Harrison, K.A., Murphy, R.C., Hinshaw, J.C.,
Prestwich, G.D., Hilaire, A.S., Prescott, S.M., Zimmerman, G.A., et al. (2001). Oxidized Alkyl
Phospholipids Are Specific, High Affinity Peroxisome Proliferator-activated Receptor Ligands
and Agonists. J. Biol. Chem. 276, 16015–16023.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single transfected cDNA
converts fibroblasts to myoblasts. Cell 51, 987–1000.
Dean, J.M., and Lodhi, I.J. (2017). Structural and functional roles of ether lipids. Protein Cell.
Dempersmier, J., Sambeat, A., Gulyaeva, O., Paul, S.M., Hudak, C.S.S., Raposo, H.F., Kwan,
H.-Y., Kang, C., Wong, R.H.F., and Sul, H.S. (2015). Cold-Inducible Zfp516 Activates UCP1
Transcription to Promote Browning of White Fat and Development of Brown Fat. Mol. Cell 57,
235–246.
Dettmann, A., Jäschke, Y., Triebel, I., Bogs, J., Schröder, I., and Schüller, H.-J. (2010). Mediator
subunits and histone methyltransferase Set2 contribute to Ino2-dependent transcriptional
activation of phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Mol. Genet.
Genomics 283, 211–221.
Ding, N., Tomomori-Sato, C., Sato, S., Conaway, R.C., Conaway, J.W., and Boyer, T.G. (2009).
MED19 and MED26 Are Synergistic Functional Targets of the RE1 Silencing Transcription
Factor in Epigenetic Silencing of Neuronal Gene Expression. J. Biol. Chem. 284, 2648–2656.
87

Eisinger, K., Krautbauer, S., Hebel, T., Schmitz, G., Aslanidis, C., Liebisch, G., and Buechler, C.
(2014). Lipidomic analysis of the liver from high-fat diet induced obese mice identifies changes
in multiple lipid classes. Exp. Mol. Pathol. 97, 37–43.
Fabelo, N., Martín, V., Santpere, G., Marín, R., Torrent, L., Ferrer, I., and Díaz, M. (2011).
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and
incidental Parkinson’s disease. Mol. Med. 17, 1107.
Facciotti, F., Ramanjaneyulu, G.S., Lepore, M., Sansano, S., Cavallari, M., Kistowska, M.,
Forss-Petter, S., Ni, G., Colone, A., Singhal, A., et al. (2012). Peroxisome-derived lipids are self
antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 13, 474–480.
Farooqui, A.A., and Horrocks, L.A. (2001). Book review: plasmalogens: workhorse lipids of
membranes in normal and injured neurons and glia. The Neuroscientist 7, 232–245.
Felder, T.K., Ring-Dimitriou, S., Auer, S., Soyal, S.M., Kedenko, L., Rinnerthaler, M.,
Cadamuro, J., Haschke-Becher, E., Aigner, E., Paulweber, B., et al. (2017). Specific circulating
phospholipids, acylcarnitines, amino acids and biogenic amines are aerobic exercise markers. J.
Sci. Med. Sport.
Fu, S., Yang, L., Li, P., Hofmann, O., Dicker, L., Hide, W., Lin, X., Watkins, S.M., Ivanov,
A.R., and Hotamisligil, G.S. (2011). Aberrant lipid metabolism disrupts calcium homeostasis
causing liver endoplasmic reticulum stress in obesity. Nature 473, 528–531.
Galic, S., Oakhill, J.S., and Steinberg, G.R. (2010). Adipose tissue as an endocrine organ. Mol.
Cell. Endocrinol. 316, 129–139.
Ge, K., Guermah, M., Yuan, C.-X., Ito, M., Wallberg, A., Spiegelman, B., and Roeder, R.
(2002). Transcription coactivator TRAP220 is required for PPARg2-stimulated adipogenesis.
Nature 417, 563–567.
Ge, K., Cho, Y.-W., Guo, H., Hong, T.B., Guermah, M., Ito, M., Yu, H., Kalkum, M., and
Roeder, R.G. (2008a). Alternative Mechanisms by Which Mediator Subunit MED1/TRAP220
Regulates Peroxisome Proliferator-Activated Receptor -Stimulated Adipogenesis and Target
Gene Expression. Mol. Cell. Biol. 28, 1081–1091.
Ge, K., Cho, Y.-W., Guo, H., Hong, T.B., Guermah, M., Ito, M., Yu, H., Kalkum, M., and
Roeder, R.G. (2008b). Alternative Mechanisms by Which Mediator Subunit MED1/TRAP220
Regulates Peroxisome Proliferator-Activated Receptor -Stimulated Adipogenesis and Target
Gene Expression. Mol. Cell. Biol. 28, 1081–1091.
Ginsberg, L., Rafique, S., Xuereb, J.H., Rapoport, S.I., and Gershfeld, N.L. (1995). Disease and
anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain
Res. 698, 223–226.
Ginsberg, L., Xuereb, J.H., and Gershfeld, N.L. (1998). Membrane instability, plasmalogen
88

content, and Alzheimer’s disease. J. Neurochem. 70, 2533–2538.
Glaser, P.E., and Gross, R.W. (1994). Plasmenylethanolamine facilitates rapid membrane fusion:
a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane
constituent to adopt an HII phase with its ability to promote membrane fusion. Biochemistry
(Mosc.) 33, 5805–5812.
Goodenowe, D.B., Cook, L.L., Liu, J., Lu, Y., Jayasinghe, D.A., Ahiahonu, P.W.K., Heath, D.,
Yamazaki, Y., Flax, J., Krenitsky, K.F., et al. (2007). Peripheral ethanolamine plasmalogen
deficiency: a logical causative factor in Alzheimer’s disease and dementia. J. Lipid Res. 48,
2485–2498.
Graessler, J., Schwudke, D., Schwarz, P.E.H., Herzog, R., Shevchenko, A., and Bornstein, S.R.
(2009). Top-Down Lipidomics Reveals Ether Lipid Deficiency in Blood Plasma of Hypertensive
Patients. PLoS ONE 4, e6261.
Grimm, M.O.W., Kuchenbecker, J., Rothhaar, T.L., Grösgen, S., Hundsdörfer, B., Burg, V.K.,
Friess, P., Müller, U., Grimm, H.S., Riemenschneider, M., et al. (2011). Plasmalogen synthesis is
regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein
processing and is affected in Alzheimer’s disease: Dysregulation of plasmalogen synthesis in
AD. J. Neurochem. 116, 916–925.
Grontved, L., Madsen, M.S., Boergesen, M., Roeder, R.G., and Mandrup, S. (2010). MED14
Tethers Mediator to the N-Terminal Domain of Peroxisome Proliferator-Activated Receptor and
Is Required for Full Transcriptional Activity and Adipogenesis. Mol. Cell. Biol. 30, 2155–2169.
Hajra, A.K., and Das, A.K. (1996). Lipid Biosynthesis in Peroxisomesa. Ann. N. Y. Acad. Sci.
804, 129–141.
Han, X. (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s
disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr.
Alzheimer Res. 2, 65–77.
Han, X.L., and Gross, R.W. (1990). Plasmenylcholine and phosphatidylcholine membrane
bilayers possess distinct conformational motifs. Biochemistry (Mosc.) 29, 4992–4996.
Han, X., Holtzman, D.M., and McKeel, D.W. (2001). Plasmalogen deficiency in early
Alzheimer’s disease subjects and in animal models: molecular characterization using
electrospray ionization mass spectrometry. J. Neurochem. 77, 1168–1180.
Harms, M., and Seale, P. (2013). Brown and beige fat: development, function and therapeutic
potential. Nat. Med. 19, 1252–1263.
Harms, M.J., Lim, H.-W., Ho, Y., Shapira, S.N., Ishibashi, J., Rajakumari, S., Steger, D.J.,
Lazar, M.A., Won, K.-J., and Seale, P. (2015). PRDM16 binds MED1 and controls chromatin
architecture to determine a brown fat transcriptional program. Genes Dev. 29, 298–307.
89

He, G.Y., Hu, J.L., Zhou, L., Zhu, X.H., Xin, S.N., Zhang, D., Lu, G.F., Liao, W.T., Ding, Y.Q.,
and Liang, L. (2016). The FOXD3/miR-214/MED19 axis suppresses tumour growth and
metastasis in human colorectal cancer. Br. J. Cancer 115, 1367–1378.
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C.,
Singh, H., and Glass, C.K. (2010). Simple Combinations of Lineage-Determining Transcription
Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. Mol.
Cell 38, 576–589.
Hillebrand, M., Gersting, S.W., Lotz-Havla, A.S., Schafer, A., Rosewich, H., Valerius, O.,
Muntau, A.C., and Gartner, J. (2012). Identification of a New Fatty Acid Synthesis-Transport
Machinery at the Peroxisomal Membrane. J. Biol. Chem. 287, 210–221.
Hofer, D.C., Pessentheiner, A.R., Pelzmann, H.J., Schlager, S., Madreiter-Sokolowski, C.T.,
Kolb, D., Eichmann, T.O., Rechberger, G., Bilban, M., Graier, W.F., et al. (2017). Critical role
of the peroxisomal protein PEX16 in white adipocyte development and lipid homeostasis.
Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids 1862, 358–368.
Honsho, M., Asaoku, S., Fukumoto, K., and Fujiki, Y. (2013). Topogenesis and Homeostasis of
Fatty Acyl-CoA Reductase 1. J. Biol. Chem. 288, 34588–34598.
Hossain, M.S., Ifuku, M., Take, S., Kawamura, J., Miake, K., and Katafuchi, T. (2013).
Plasmalogens Rescue Neuronal Cell Death through an Activation of AKT and ERK Survival
Signaling. PLoS ONE 8, e83508.
Hossain, M.S., Mineno, K., and Katafuchi, T. (2016). Neuronal Orphan G-Protein Coupled
Receptor Proteins Mediate Plasmalogens-Induced Activation of ERK and Akt Signaling. PLOS
ONE 11, e0150846.
Hua, R., Cheng, D., Coyaud, É., Freeman, S., Di Pietro, E., Wang, Y., Vissa, A., Yip, C.M.,
Fairn, G.D., Braverman, N., et al. (2017). VAPs and ACBD5 tether peroxisomes to the ER for
peroxisome maintenance and lipid homeostasis. J. Cell Biol. jcb.201608128.
Huang, J.H., Park, H., Iaconelli, J., Berkovitch, S.S., Watmuff, B., McPhie, D., Öngür, D.,
Cohen, B.M., Clish, C.B., and Karmacharya, R. (2016). Unbiased Metabolite Profiling of
Schizophrenia Fibroblasts under Stressful Perturbations Reveals Dysregulation of Plasmalogens
and Phosphatidylcholines. J. Proteome Res.
Huang, L., Pan, D., Chen, Q., Zhu, L.J., Ou, J., Wabitsch, M., and Wang, Y.-X. (2017).
Transcription factor Hlx controls a systematic switch from white to brown fat through Prdm16mediated co-activation. Nat. Commun. 8.
Iida, S., Chen, W., Nakadai, T., Ohkuma, Y., and Roeder, R.G. (2015). PRDM16 enhances
nuclear receptor-dependent transcription of the brown fat-specific Ucp1 gene through
interactions with Mediator subunit MED1. Genes Dev. 29, 308–321.
90

James, P.F., Lake, A.C., Hajra, A.K., Larkins, L.K., Robinson, M., Buchanan, F.G., and Zoeller,
R.A. (1997). An Animal Cell Mutant with a Deficiency in Acyl/Alkyl-dihydroxyacetonephosphate Reductase Activity: Effects on the Biosynthesis of Ether-linked and Diacyl
Glycerolipids. J. Biol. Chem. 272, 23540–23546.
Jang, J.E., Park, H.-S., Yoo, H.J., Baek, I.-J., Yoon, J.E., Ko, M.S., Kim, A.-R., Kim, H.S., Park,
H.-S., Lee, S.E., et al. (2017). Protective role of endogenous plasmalogens against hepatic
steatosis and steatohepatitis. Hepatology.
Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P., and Spiegelman,
B.M. (2009). Initiation of myoblast to brown fat switch by a PRDM16–C/EBP-β transcriptional
complex. Nature 460, 1154–1158.
Kajimura, S., Spiegelman, B.M., and Seale, P. (2015). Brown and Beige Fat: Physiological Roles
beyond Heat Generation. Cell Metab. 22, 546–559.
Khaselev, N., and Murphy, R.C. (1999). Susceptibility of plasmenyl
glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free
Radic. Biol. Med. 26, 275–284.
Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. (1998). ADD1 SREBP1 activates
PPAR through the production of endogenous ligand. PNAS 95, 4333–4337.
Kin Chan, S.S. (2013). What is a Master Regulator? J. Stem Cell Res. Ther. 3.
Komljenovic, D., Sandhoff, R., Teigler, A., Heid, H., Just, W.W., and Gorgas, K. (2009).
Disruption of blood-testis barrier dynamics in ether-lipid-deficient mice. Cell Tissue Res. 337,
281–299.
Kumar, M.S., Pester, R.E., Chen, C.Y., Lane, K., Chin, C., Lu, J., Kirsch, D.G., Golub, T.R., and
Jacks, T. (2009). Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23,
2700–2704.
LaBelle, E.F., and Hajra, A.K. (1974). Purification and Kinetic Properties of Acyl and Alkyl
Dihydroxyacetone Phosphate Oxidoreductase. J. Biol. Chem. 249, 6936–6944.
Lankinen, M., Schwab, U., Kolehmainen, M., Paananen, J., Nygren, H., Seppa nen-Laakso, T.,
Poutanen, K., Hyo tyla inen, T., Riserus, U., Savolainen, M.J., et al. (2016). A Healthy Nordic
Diet Alters the Plasma Lipidomic Profile in Adults with Features of Metabolic Syndrome in a
Multicenter Randomized Dietary Intervention. J. Nutr. 146, 662–672.
Lefterova, M.I., Steger, D.J., Zhuo, D., Qatanani, M., Mullican, S.E., Tuteja, G., Manduchi, E.,
Grant, G.R., and Lazar, M.A. (2010). Cell-Specific Determinants of Peroxisome ProliferatorActivated Receptor Function in Adipocytes and Macrophages. Mol. Cell. Biol. 30, 2078–2089.
Li, Z., Agellon, L.B., Allen, T.M., Umeda, M., Jewell, L., Mason, A., and Vance, D.E. (2006).
91

The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity
and steatohepatitis. Cell Metab. 3, 321–331.
Linhart, H.G., Ishimura-Oka, K., DeMayo, F., Kibe, T., Repka, D., Poindexter, B., Bick, R.J.,
and Darlington, G.J. (2001). C/EBPα is required for differentiation of white, but not brown,
adipose tissue. Proc. Natl. Acad. Sci. 98, 12532–12537.
Liu, B., Qi, X., Zhang, X., Gao, D., Fang, K., Guo, Z., and Li, L. (2018). Med19 is involved in
chemoresistance by mediating autophagy through HMGB1 in breast cancer: LIU ET AL . J. Cell.
Biochem.
Liu, Z., Yao, X., Yan, G., Xu, Y., Yan, J., Zou, W., and Wang, G. (2016). Mediator MED23
cooperates with RUNX2 to drive osteoblast differentiation and bone development. Nat.
Commun. 7.
Lodhi, I.J., Yin, L., Jensen-Urstad, A.P.L., Funai, K., Coleman, T., Baird, J.H., El Ramahi, M.K.,
Razani, B., Song, H., Fu-Hsu, F., et al. (2012). Inhibiting Adipose Tissue Lipogenesis
Reprograms Thermogenesis and PPARγ Activation to Decrease Diet-Induced Obesity. Cell
Metab. 16, 189–201.
Lodhi, I.J., Wei, X., Yin, L., Feng, C., Adak, S., Abou-Ezzi, G., Hsu, F.-F., Link, D.C., and
Semenkovich, C.F. (2015). Peroxisomal Lipid Synthesis Regulates Inflammation by Sustaining
Neutrophil Membrane Phospholipid Composition and Viability. Cell Metab. 21, 51–64.
Lodhi, I.J., Dean, J.M., He, A., Park, H., Tan, M., Feng, C., Song, H., Hsu, F.-F., and
Semenkovich, C.F. (2017). PexRAP Inhibits PRDM16-Mediated Thermogenic Gene Expression.
Cell Rep. 20, 2766–2774.
Lohner, K. (1996). Is the high propensity of ethanolamine plasmalogens to form non-lamellar
lipid structures manifested in the properties of biomembranes? Chem. Phys. Lipids 81, 167–184.
Long, J.Z., Svensson, K.J., Tsai, L., Zeng, X., Roh, H.C., Kong, X., Rao, R.R., Lou, J.,
Lokurkar, I., Baur, W., et al. (2014). A Smooth Muscle-Like Origin for Beige Adipocytes. Cell
Metab. 19, 810–820.
Luoma, A.M., Kuo, F., Cakici, O., Crowther, M.N., Denninger, A.R., Avila, R.L., Brites, P., and
Kirschner, D.A. (2015). Plasmalogen phospholipids protect internodal myelin from oxidative
damage. Free Radic. Biol. Med. 84, 296–310.
Maeba, R., and Ueta, N. (2003). Ethanolamine plasmalogen and cholesterol reduce the total
membrane oxidizability measured by the oxygen uptake method. Biochem. Biophys. Res.
Commun. 302, 265–270.
Maeba, R., Sawada, Y., Shimasaki, H., Takahashi, I., and Ueta, N. (2002). Ethanolamine
plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free
radicals. Chem. Phys. Lipids 120, 145–151.
92

van Marken Lichtenbelt, W.D., Vanhommerig, J.W., Smulders, N.M., Drossaerts, J.M.,
Kemerink, G.J., Bouvy, N.D., Schrauwen, P., and Teule, G.J. (2009). Cold-activated brown
adipose tissue in healthy men. N. Engl. J. Med. 360, 1500–1508.
Marrink, S.-J., and Mark, A.E. (2004). Molecular View of Hexagonal Phase Formation in
Phospholipid Membranes. Biophys. J. 87, 3894–3900.
McIntyre, T.M., Pontsler, A.V., Silva, A.R., Hilaire, A.S., Xu, Y., Hinshaw, J.C., Zimmerman,
G.A., Hama, K., Aoki, J., Arai, H., et al. (2003). Identification of an intracellular receptor for
lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. 100,
131–136.
Morand, O.H., Zoeller, R.A., and Raetz, C.R. (1988). Disappearance of plasmalogens from
membranes of animal cells subjected to photosensitized oxidation. J. Biol. Chem. 263, 11597–
11606.
Motley, A.M., Hettema, E.H., Hogenhout, E.M., Brites, P., ten Asbroek, A.L., Wijburg, F.A.,
Baas, F., Heijmans, H.S., Tabak, H.F., and Wanders, R.J. (1997). Rhizomelic chondrodysplasia
punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor.
Nat. Genet. 15, 377–380.
Mueller, H.W., O’Flaherty, J.T., and Wykle, R.L. (1982). Ether lipid content and fatty acid
distribution in rabbit polymorphonuclear neutrophil phospholipids. Lipids 17, 72–77.
Mueller, H.W., O’Flaherty, J.T., Greene, D.G., Samuel, M.P., and Wykle, R.L. (1984). 1-Oalkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other
acyl residues in the ether-linked and diacyl species. J. Lipid Res. 25, 383–388.
Munn, N.J. (2003). Deficiency in ethanolamine plasmalogen leads to altered cholesterol
transport. J. Lipid Res. 44, 182–192.
Nagan, N., and Zoeller, R.A. (2001). Plasmalogens: biosynthesis and functions. Prog. Lipid Res.
40, 199–299.
Nakamura, Y., Yamamoto, K., He, X., Otsuki, B., Kim, Y., Murao, H., Soeda, T., Tsumaki, N.,
Deng, J.M., Zhang, Z., et al. (2011). Wwp2 is essential for palatogenesis mediated by the
interaction between Sox9 and mediator subunit 25. Nat. Commun. 2.
Ogden, C.L., Carroll, M.D., Kit, B.K., and Flegal, K.M. (2014). Prevalence of childhood and
adult obesity in the United States, 2011-2012. Jama 311, 806–814.
Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura, G., Maemura,
K., Yamauchi, T., Kubota, N., et al. (2005). Krüppel-like transcription factor KLF5 is a key
regulator of adipocyte differentiation. Cell Metab. 1, 27–39.
Orešič, M., Simell, S., Sysi-Aho, M., Näntö-Salonen, K., Seppänen-Laakso, T., Parikka, V.,
93

Katajamaa, M., Hekkala, A., Mattila, I., Keskinen, P., et al. (2008). Dysregulation of lipid and
amino acid metabolism precedes islet autoimmunity in children who later progress to type 1
diabetes. J. Exp. Med. 205, 2975–2984.
Ouchi, N., Parker, J.L., Lugus, J.J., and Walsh, K. (2011). Adipokines in inflammation and
metabolic disease. Nat. Rev. Immunol. 11, 85–97.
Paltauf, F. (1994). Ether lipids in biomembranes. Chem. Phys. Lipids 74, 101–139.
Park, H., He, A., and Lodhi, I.J. (2019a). Lipid Regulators of Thermogenic Fat Activation.
Trends Endocrinol. Metab. 30, 710–723.
Park, H., He, A., Tan, M., Johnson, J.M., Dean, J.M., Pietka, T.A., Chen, Y., Zhang, X., Hsu, F.F., Razani, B., et al. (2019b). Peroxisome-derived lipids regulate adipose thermogenesis by
mediating cold-induced mitochondrial fission. J. Clin. Invest.
Park, H.S., Ju, U.I., Park, J.-W., Song, J.Y., Shin, D.H., Lee, K.H., Jeong, L.S., Yu, J., Lee,
H.W., and Cho, J.Y. (2016). PPARγ neddylation essential for adipogenesis is a potential target
for treating obesity. Cell Death Differ. 23, 1296.
Piano, V., Benjamin, D.I., Valente, S., Nenci, S., Marrocco, B., Mai, A., Aliverti, A., Nomura,
D.K., and Mattevi, A. (2015). Discovery of Inhibitors for the Ether Lipid-Generating Enzyme
AGPS as Anti-Cancer Agents. ACS Chem. Biol. 10, 2589–2597.
Pietiläinen, K.H., Sysi-Aho, M., Rissanen, A., Seppänen-Laakso, T., Yki-Järvinen, H., Kaprio,
J., and Orešič, M. (2007). Acquired Obesity Is Associated with Changes in the Serum Lipidomic
Profile Independent of Genetic Effects – A Monozygotic Twin Study. PLoS ONE 2, e218.
Pietiläinen, K.H., Róg, T., Seppänen-Laakso, T., Virtue, S., Gopalacharyulu, P., Tang, J.,
Rodriguez-Cuenca, S., Maciejewski, A., Naukkarinen, J., Ruskeepää, A.-L., et al. (2011).
Association of Lipidome Remodeling in the Adipocyte Membrane with Acquired Obesity in
Humans. PLoS Biol. 9, e1000623.
Pike, L.J., Han, X., Chung, K.-N., and Gross, R.W. (2002). Lipid Rafts Are Enriched in
Arachidonic Acid and Plasmenylethanolamine and Their Composition Is Independent of
Caveolin-1 Expression: A Quantitative Electrospray Ionization/Mass Spectrometric Analysis †.
Biochemistry (Mosc.) 41, 2075–2088.
Purdue, P.E. (1997). Rhizomelic chondrodysplasia punctata is caused by deficiency of human
PEX7, a homologue of the yeast PTSZ. Nat. Genet. 15, 381.
Puri, P., Wiest, M.M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H.-K., Contos, M.J., Sterling,
R.K., Fuchs, M., Zhou, H., et al. (2009). The plasma lipidomic signature of nonalcoholic
steatohepatitis. Hepatology 50, 1827–1838.
Rajakumari, S., Wu, J., Ishibashi, J., Lim, H.-W., Giang, A.-H., Won, K.-J., Reed, R.R., and
94

Seale, P. (2013). EBF2 Determines and Maintains Brown Adipocyte Identity. Cell Metab. 17,
562–574.
Rao Kondapally Seshasai, S., Kaptoge, S., Thompson, A., Di Angelantonio, E., Gao, P., Sarwar,
N., Whincup, P.H., Mukamal, K.J., Gillum, R.F., and Holme, I. (2011). Diabetes mellitus,
fasting glucose, and risk of cause-specific death. N Engl J Med 364, 829–841.
Rasmiena, A.A., Barlow, C.K., Stefanovic, N., Huynh, K., Tan, R., Sharma, A., Tull, D., de
Haan, J.B., and Meikle, P.J. (2015). Plasmalogen modulation attenuates atherosclerosis in ApoEand ApoE/GPx1-deficient mice. Atherosclerosis 243, 598–608.
Reiss, D., Beyer, K., and Engelmann, B. (1997). Delayed oxidative degradation of
polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro.
Biochem. J. 323, 807–814.
Rochford, J.J. (2014). Mouse Models of Lipodystrophy and Their Significance in Understanding
Fat Regulation. In Current Topics in Developmental Biology, (Elsevier), pp. 53–96.
Rodemer, C., Thai, T.-P., Brugger, B., Kaercher, T., Werner, H., Nave, K.-A., Wieland, F.,
Gorgas, K., and Just, W.W. (2003). Inactivation of ether lipid biosynthesis causes male
infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 12,
1881–1895.
RooS, D.S., and Choppin, P.W. (1984). Tumorigenicity of cell lines with altered lipid
composition. Proc. Natl. Acad. Sci. 81, 7622–7626.
Rosen, E.D., and Spiegelman, B.M. (2014). What We Talk About When We Talk About Fat.
Cell 156, 20–44.
Rosen, E.D., hsu, C.-H., Wang, X., Sakai, S., Freeman, M.W., Gonzalez, F.J., and Spiegelman,
B.M. (2002). C/EBPa induces adipogenesis through PPARy: a unified pathway. Genes Dev. 22–
26.
de Sá, P.M., Richard, A.J., Hang, H., and Stephens, J.M. (2017). Transcriptional Regulation of
Adipogenesis. In Comprehensive Physiology, R. Terjung, ed. (Hoboken, NJ, USA: John Wiley
& Sons, Inc.), pp. 635–674.
Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., and
Sabatini, D.M. (2008). The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to
mTORC1. Science 320, 1496–1501.
Sanchez-Gurmaches, J., and Guertin, D.A. (2014). Adipocytes arise from multiple lineages that
are heterogeneously and dynamically distributed. Nat. Commun. 5.
Sanchez-Gurmaches, J., Hung, C.-M., and Guertin, D.A. (2016). Emerging Complexities in
Adipocyte Origins and Identity. Trends Cell Biol. 26, 313–326.
95

Savage, D.B. (2009). Mouse models of inherited lipodystrophy. Dis. Model. Mech. 2, 554–562.
Schroeder, T.M., Jensen, E.D., and Westendorf, J.J. (2005). Runx2: A master organizer of gene
transcription in developing and maturing osteoblasts. Birth Defects Res. Part C Embryo Today
Rev. 75, 213–225.
Seale, P., Kajimura, S., Yang, W., Chin, S., Rohas, L.M., Uldry, M., Tavernier, G., Langin, D.,
and Spiegelman, B.M. (2007). Transcriptional Control of Brown Fat Determination by PRDM16.
Cell Metab. 6, 38–54.
Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scimè, A., Devarakonda, S.,
Conroe, H.M., Erdjument-Bromage, H., et al. (2008). PRDM16 controls a brown fat/skeletal
muscle switch. Nature 454, 961–967.
Shao, M., Wang, Q.A., Song, A., Vishvanath, L., Busbuso, N.C., Scherer, P.E., and Gupta, R.K.
(2019). Cellular Origins of Beige Fat Cells Revisited. Diabetes 68, 1874–1885.
da Silva, T.F., Sousa, V.F., Malheiro, A.R., and Brites, P. (2012). The importance of etherphospholipids: A view from the perspective of mouse models. Biochim. Biophys. Acta BBA Mol. Basis Dis. 1822, 1501–1508.
da Silva, T.F., Eira, J., Lopes, A.T., Malheiro, A.R., Sousa, V., Luoma, A., Avila, R.L.,
Wanders, R.J.A., Just, W.W., Kirschner, D.A., et al. (2014). Peripheral nervous system
plasmalogens regulate Schwann cell differentiation and myelination. J. Clin. Invest. 124, 2560–
2570.
Skaff, O., Pattison, D.I., and Davies, M.J. (2008). The Vinyl Ether Linkages of Plasmalogens
Are Favored Targets for Myeloperoxidase-Derived Oxidants: A Kinetic Study †. Biochemistry
(Mosc.) 47, 8237–8245.
Snyder, F. (1999). The ether lipid trail: a historical perspective. Biochim. Biophys. Acta BBAMol. Cell Biol. Lipids 1436, 265–278.
Snyder, F., and Wood, R. (1969). Alkyl and alk-1-enyl ethers of glycerol in lipids from normal
and neoplastic human tissues. Cancer Res. 29, 251–257.
Snyder, F., Cress, E.A., and Stephens, N. (1966). An unidentified lipid prevalent in tumors.
Lipids 1, 381–386.
Snyder, F., Blank, M.L., and Morris, H.P. (1969). Occurrence and nature of O-alkyl and O-alk-1enyl moieties of glycerol in lipids of Morris transplanted hepatomas and normal rat liver.
Biochim. Biophys. Acta BBA-Lipids Lipid Metab. 176, 502–510.
Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F.H., Goehler, H., Stroedicke, M.,
Zenkner, M., Schoenherr, A., Koeppen, S., et al. (2005). A Human Protein-Protein Interaction
Network: A Resource for Annotating the Proteome. Cell 122, 957–968.
96

Svensson, K.J., Long, J.Z., Jedrychowski, M.P., Cohen, P., Lo, J.C., Serag, S., Kir, S., Shinoda,
K., Tartaglia, J.A., Rao, R.R., et al. (2016). A Secreted Slit2 Fragment Regulates Adipose Tissue
Thermogenesis and Metabolic Function. Cell Metab. 23, 454–466.
Teigler, A., D. Komljenovic, Draguhn, A., Gorgas, K., and Just, W.W. (2009). Defects in
myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient
mouse cerebellum. Hum. Mol. Genet. 18, 1897–1908.
Tessier, C., Sweers, K., Frajerman, A., Bergaoui, H., Ferreri, F., Delva, C., Lapidus, N.,
Lamaziere, A., Roiser, J.P., De Hert, M., et al. (2016). Membrane lipidomics in schizophrenia
patients: a correlational study with clinical and cognitive manifestations. Transl. Psychiatry 6,
e906.
Thukkani, A.K., Hsu, F.-F., Crowley, J.R., Wysolmerski, R.B., Albert, C.J., and Ford, D.A.
(2002). Reactive Chlorinating Species Produced during Neutrophil Activation Target Tissue
Plasmalogens: PRODUCTION OF THE CHEMOATTRACTANT, 2CHLOROHEXADECANAL. J. Biol. Chem. 277, 3842–3849.
Tontonoz, P., and Spiegelman, B.M. (2008). Fat and Beyond: The Diverse Biology of PPARγ.
Annu. Rev. Biochem. 77, 289–312.
Tontonoz, P., Hu, E., and Spiegelman, B.M. (1994). Stimulation of adipogenesis in fibroblasts
by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156.
Tsukahara, T., Tsukahara, R., Yasuda, S., Makarova, N., Valentine, W.J., Allison, P., Yuan, H.,
Baker, D.L., Li, Z., Bittman, R., et al. (2006). Different Residues Mediate Recognition of 1-OOleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome
Proliferator-activated Receptor. J. Biol. Chem. 281, 3398–3407.
Tulodziecka, K., Diaz-Rohrer, B.B., Farley, M.M., Chan, R.B., Di Paolo, G., Levental, K.R.,
Waxham, M.N., and Levental, I. (2016). Remodeling of the postsynaptic plasma membrane
during neural development. Mol. Biol. Cell 27, 3480–3489.
Tutter, A.V., Kowalski, M.P., Baltus, G.A., Iourgenko, V., Labow, M., Li, E., and Kadam, S.
(2009). Role for Med12 in Regulation of Nanog and Nanog Target Genes. J. Biol. Chem. 284,
3709–3718.
Tzameli, I., Fang, H., Ollero, M., Shi, H., Hamm, J.K., Kievit, P., Hollenberg, A.N., and Flier,
J.S. (2004). Regulated Production of a Peroxisome Proliferator-activated Receptor- Ligand
during an Early Phase of Adipocyte Differentiation in 3T3-L1 Adipocytes. J. Biol. Chem. 279,
36093–36102.
Villanueva, C.J., Waki, H., Godio, C., Nielsen, R., Chou, W.-L., Vargas, L., Wroblewski, K.,
Schmedt, C., Chao, L.C., Boyadjian, R., et al. (2011). TLE3 Is a Dual-Function Transcriptional
Coregulator of Adipogenesis. Cell Metab. 13, 413–427.
97

Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M.,
Laine, J., Savisto, N.-J., Enerbäck, S., et al. (2009). Functional brown adipose tissue in healthy
adults. N. Engl. J. Med. 360, 1518–1525.
Viscarra, J.A., Wang, Y., Hong, I.-H., and Sul, H.S. (2017). Transcriptional activation of
lipogenesis by insulin requires phosphorylation of MED17 by CK2. Sci Signal 10, eaai8596.
Vitali, A., Murano, I., Zingaretti, M.C., Frontini, A., Ricquier, D., and Cinti, S. (2012). The
adipose organ of obesity-prone C57BL/6J mice is composed of mixed white and brown
adipocytes. J. Lipid Res. 53, 619–629.
Volmer, R., van der Ploeg, K., and Ron, D. (2013). Membrane lipid saturation activates
endoplasmic reticulum unfolded protein response transducers through their transmembrane
domains. Proc. Natl. Acad. Sci. 110, 4628–4633.
Wang, Y.-X. (2010). PPARs: diverse regulators in energy metabolism and metabolic diseases.
Cell Res. 20, 124–137.
Wang, G., and Wang, T. (2010). The Role of Plasmalogen in the Oxidative Stability of Neutral
Lipids and Phospholipids. J. Agric. Food Chem. 58, 2554–2561.
Wang, F., Mullican, S.E., DiSpirito, J.R., Peed, L.C., and Lazar, M.A. (2013). Lipoatrophy and
severe metabolic disturbance in mice with fat-specific deletion of PPAR. Proc. Natl. Acad. Sci.
110, 18656–18661.
Wang, W., Huang, L., Huang, Y., Yin, J., Berk, A.J., Friedman, J.M., and Wang, G. (2009).
Mediator MED23 Links Insulin Signaling to the Adipogenesis Transcription Cascade. Dev. Cell
16, 764–771.
Wen, H., Feng, C., Ding, G., Meng, D., Ding, Q., Fang, Z., Xia, G., Xu, G., and Jiang, H. (2013).
Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone
morphogenetic protein 2. Ann. Diagn. Pathol. 17, 259–264.
White, A.L., Modaff, P., Holland-Morris, F., and Pauli, R.M. (2003). Natural history of
rhizomelic chondrodysplasia punctata. Am. J. Med. Genet. 118A, 332–342.
Wood, P., mankidy, R., Ritchie, S., Heath, D., Wood, J.A., Flax, J., and Goodenowe, D. (2010).
Circulating plasmalogen levels and Alzheimer Disease Assessment Scale–Cognitive scores in
Alzheimer patients. J. Psychiatry Neurosci. 35, 59–62.
Wood, P.L., Locke, V.A., Herling, P., Passaro, A., Vigna, G.B., Volpato, S., Valacchi, G.,
Cervellati, C., and Zuliani, G. (2016). Targeted lipidomics distinguishes patient subgroups in
mild cognitive impairment (MCI) and late onset Alzheimer’s disease (LOAD). BBA Clin. 5, 25–
28.
Yamashita, S., Kanno, S., Nakagawa, K., Kinoshita, M., and Miyazawa, T. (2015a). Extrinsic
98

plasmalogens suppress neuronal apoptosis in mouse neuroblastoma Neuro-2A cells: importance
of plasmalogen molecular species. RSC Adv 5, 61012–61020.
Yamashita, S., Kiko, T., Fujiwara, H., Hashimoto, M., Nakagawa, K., Kinoshita, M., Furukawa,
K., Arai, H., and Miyazawa, T. (2015b). Alterations in the Levels of Amyloid-β, Phospholipid
Hydroperoxide, and Plasmalogen in the Blood of Patients with Alzheimer’s Disease: Possible
Interactions between Amyloid-β and These Lipids. J. Alzheimers Dis. 50, 527–537.
Yavin, E., and Gatt, S. (1972). Oxygen-Dependent Cleavage of the Vinyl-Ether Linkage of
Plasmalogens. Eur. J. Biochem. 25, 437–446.
Yen, C.-L.E., Mar, M., and Zeisel, S.H. (1999). Choline deficiency-induced apoptosis in PC12
cells is associated with diminished membrane phosphatidylcholine and sphingomyelin,
accumulation of ceramide and diacylglycerol, and activation of a caspase. FASEB J. 13, 135–
142.
Yin, J. -w., Liang, Y., Park, J.Y., Chen, D., Yao, X., Xiao, Q., Liu, Z., Jiang, B., Fu, Y., Bao, M.,
et al. (2012). Mediator MED23 plays opposing roles in directing smooth muscle cell and
adipocyte differentiation. Genes Dev. 26, 2192–2205.
Zhang, C., Baker, D.L., Yasuda, S., Makarova, N., Balazs, L., Johnson, L.R., Marathe, G.K.,
McIntyre, T.M., Xu, Y., Prestwich, G.D., et al. (2004). Lysophosphatidic Acid Induces
Neointima Formation Through PPARγ Activation. J. Exp. Med. 199, 763–774.
Zhang, Y., Xiaoli, X.Z., and Yang, F. (2013). The mediator complex and lipid metabolism. J.
Biochem. Pharmacol. Res. 1, 51.
Zhou, R., Bonneaud, N., Yuan, C.-X., de Santa Barbara, P., Boizet, B., Tibor, S., Scherer, G.,
Roeder, R.G., Poulat, F., and Berta, P. (2002). SOX9 interacts with a component of the human
thyroid hormone receptor‐associated protein complex. Nucleic Acids Res. 30, 3245–3252.
Zingaretti, M.C., Crosta, F., Vitali, A., Guerrieri, M., Frontini, A., Cannon, B., Nedergaard, J.,
and Cinti, S. (2009). The presence of UCP1 demonstrates that metabolically active adipose tissue
in the neck of adult humans truly represents brown adipose tissue. FASEB J. 23, 3113–3120.
Zoeller, R.A., Morand, O.H., and Raetz, C.R. (1988). A Possible Role for Plasmalogens in
Protecting Animal Cells against Photosensitized Killing. J. Biol. Chem. 263, 11590–11596.
Zuo, Y., Qiang, L., and Farmer, S.R. (2006). Activation of CCAAT/Enhancer-binding Protein
(C/EBP) α Expression by C/EBPβ during Adipogenesis Requires a Peroxisome Proliferatoractivated Receptor-γ-associated Repression of HDAC1 at the C/EBPα Gene Promoter. J. Biol.
Chem. 281, 7960–7967.

99

